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ABSTRACT
  Obesity is an inflammatory disease involving accumulation of adipose 
tissue, gut microbiota dysbiosis, and over-activation of the endocannabinoid 
system (ECS). Mechanisms involved in ECS regulation of obesity-induced 
inflammation are not well understood. Presented here are three chapters 
involving microRNA (miR) regulation of inflammatory adipose tissue 
macrophages (ATM) during high-fat diet (HFD)-induced obesity and cannabinoid 
receptor-mediated regulation of gut microbiota dysbiosis.  
ATMs are innate immune cells that drive chronic low-grade inflammation 
during obesity. Polarization between pro-(M1) and anti-(M2-like) inflammatory 
phenotypes influence insulin sensitivity and energy expenditure; however, the 
mechanisms involved are unclear. In study one, we characterized miRs involved 
in ATM polarization during diet-induced obesity (DIO). In study two, DIO mice 
were treated with the cannabinoid receptor 1 (CB1) antagonist AM251 because 
CB1 antagonists ameliorate DIO and associated inflammation. In both studies, it 
was found that the miR-30 family regulates ATM Delta-like-4 (DLL4)-Notch 
signaling, and consequently ATM polarization. Downregulation of miRs 30a-5p, 
30c-5p, and 30e-5p in ATMs from DIO mice versus lean mice resulted in Notch-
signaling induced M1 polarization. Interestingly, miR-30e-5p was upregulated in 
ATMs from DIO mice treated with AM251, while DLL4 was downregulated. 
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Subsequently, fat storage and M1 ATM polarization was reduced. Furthermore, 
AM251-treated macrophages suppressed DLL4-mediated Th1 polarization in 
CD4+ T cells. The combined effect of miR-30 in ATMs and consequently T cells 
led to an anti-inflammatory state and attenuation of diet-induced obesity 
regulated by CB1 blockade. 
In the third study, CB1-/- and CB2-/- mice as well as AM251 DIO 
intervention were used to investigate ECS regulation of DIO-associated gut 
dysbiosis. CB1-/- mice displayed resistance, whereas, CB2-/- mice displayed 
accelerated DIO development versus wild-type (WT) mice. Interestingly, CB1 and 
CB2 reciprocally regulated HFD-induced leukocyte infiltration in the cecal-colonic 
lamina propria. Microbiota profiling showed that CB1-/-, but not WT or CB2-/- mice 
were resistant to development of HFD-induced gut dysbiosis. Moreover, AM251 
intervention in obese mice shifted their microbiota towards a lean profile. 
Investigation of host: microbiota interactions revealed ECS-mediated regulation 
of intestinal barrier defense and gut microbiota-mediated sugar metabolism were 
involved in the pathogenesis of obesity.  
Together, our studies demonstrate that DIO is regulated by 
endocannabinoids through alterations in miRNA and microbiota that regulate 
inflammation. Thus, approaches aimed at modulating such pathways may 
provide novel therapeutic modalities to treat obesity.   
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The World Health Organization (WHO) defines obesity as “excessive fat 
accumulation that presents a risk to health”. Its incidence has reached epidemic 
proportions and continues to rise. WHO reports from 2016 indicated that over 1.9 
billion adults were overweight or obese worldwide. That equates to approximately 
39% of the global population. Furthermore, the WHO estimated over 340 million 
children and adolescents were considered overweight or obese in 2016. These 
data are an obvious indication that obesity is a major health concern that requires 
attention. 
Obesity has been an issue for centuries; however, in 2008 The Obesity 
Society presented evidence to advocate characterization of obesity as a disease 
(Allison et al., 2008). After much debate, the American Medical Association 
officially declared obesity as a disease in 2013, which allowed increased 
research and access to healthcare (Kyle et al., 2016). Eventual declaration of 
obesity as a disease can be attributed to its correlation with development of 
comorbid disorders such as type II diabetes, cardiovascular diseases, and some 
types of cancers, which together, put a large burden on the healthcare system 
(Redinger, 2007). Obesity is a preventable yet chronic condition that can be 
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cured with the right lifestyle modifications or interventions. Causes of obesity 
include environmental factors such as poor diet composition, overeating, and 
sedentary lifestyle, as well as, genetic predisposition (Haslam and James, 2005). 
It is reported that many physiological processes and interactions contribute to 
obesity such as inflammation, the endocannabinoid system, and the intestinal 
flora (Cota et al., 2003; Lumeng et al., 2007; Muccioli et al., 2010; Sonnenburg 
and Bäckhed, 2016). Still, there is much to be learned about the complex etiology 
of this disease in order to develop more efficient therapeutic interventions. 
1.2 METABOLIC INFLAMMATION 
Inflammation is the underlying cause of many diseases including obesity.  
During obesity, inflammation occurs in various metabolic organs including the 
adipose tissue, liver, muscle, and intestinal tract, which promote a state of 
chronic sub-clinical systemic inflammation that encourages metabolic dysfunction 
(Lackey and Olefsky, 2016). Specific to this dissertation, adipose tissue 
inflammation and intestinal immunity are investigated.  
In adipose tissue, increased adiposity, particularly visceral fat expansion, 
promotes metabolic inflammation. Importantly, inflammation originating from 
adipose tissue is thought to initiate the development of obesity-induced insulin 
resistance and type II diabetes (Xu et al., 2003).  Adipocyte hypertrophy and 
hyperplasia results in stress-induced cell death and release of pro-inflammatory 
adipokines as well as damage-associated molecular patterns that recruit immune 
cells into the adipose tissue to clean up damage (Sun et al., 2012). Recruited 
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immune cells produce additional pro-inflammatory cytokines to promote chronic 
low-grade inflammation (Fontana et al., 2007). Macrophages are myeloid-derived 
phagocytic cells of the innate immune system that make up a majority of the 
immune infiltrate to dominate the adipose tissue by both phenotype and number 
(Boutens and Stienstra, 2016; Red Eagle and Chawla, 2010; Weisberg et al., 
2003; Xu et al., 2003). They are capable of polarizing between a broad spectrum 
of pro- and anti- inflammatory phenotypes (routinely classified as M1 and M2, 
respectively) and several subsets have been described that are involved in not 
only inflammatory responses but also in buffering lipolysis by storing lipids and 
preventing their release into circulation (Boutens and Stienstra, 2016; Hamilton et 
al., 2014; Mantovani et al., 2002). Lean adipose tissue contains resident M2-like 
ATMs that are uniformly dispersed and secrete anti-inflammatory cytokines such 
as IL-4, TGFβ, and IL-10 to maintain insulin sensitivity and tissue homeostasis 
(Fujisaka et al., 2009). Obesity promotes infiltration, retention, proliferation, and 
polarization of pro-inflammatory M1 ATMs that dominate the tissue, form crown-
like-structures around necrotic adipocytes, and produce pro-inflammatory 
cytokines such as TNFα, IL-1β, MCP-1, and IL-6 that decrease insulin sensitivity, 
increase adipocyte lipolysis, and recruit additional immune cells (Olefsky and 
Glass, 2010). Microscopy images of epididymal fat from lean and diet-induced 
obese mice illustrate these phenotypic differences of adipocyte and ATM 
morphology (Figure 1.1). Due to vast disparities observed in ATM functionality 
and number between lean and obese individuals, ATMs play a critical role in 
determining development of obesity-related pathologies. Therapeutic strategies 
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that lessen ATM inflammation would be beneficial to reduce obesity and 
comorbid disorders such as insulin resistance (Fujisaka et al., 2009; Sun et al., 
2012).  
Intestinal inflammation is another contributor to obesity-induced metabolic 
dysfunction. The intestinal immune system is comprised of mucus, intestinal 
epithelial cells (IECs), innate lymphoid cells, as well as other innate and adaptive 
immune cells that reside in the intraepithelial layer or lamina propria (Winer et al., 
2016). During homeostasis, IECs secrete protective mucus and antimicrobial 
peptides that prevent microbial breach of the intestinal barrier (Winer et al., 
2016). Innate immune cells and regulatory T cells also produce anti-inflammatory 
mediators such as IL-22 and IL-10 that promote tolerance and barrier integrity 
(Winer et al., 2016). During obesity, intestinal immunity is altered due to changes 
in composition and interaction with the gut microbiota. Pro-inflammatory T cells 
produce IFNγ and IL-17. Resultant intestinal permeability allows microbe 
associated molecular patterns, such as lipopolysaccharide (LPS), to enter 
circulation and activate innate immune responses through toll-like receptor 4 and 
it’s co-receptor CD14 (Zhang et al., 2019). Thus, LPS in circulation stimulates 
metabolic endotoxemia and pro-inflammatory cytokine production that promotes 
adipose tissue insulin resistance and is thought to be a main initiator of obesity-
induced metabolic dysfunction (Cani et al., 2007, 2008). Together, these data 
indicate that maintenance of intestinal barrier homeostasis is crucial for 
protecting against metabolic dysfunction.  
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1.3 ENDOCANNABINOID SYSTEM 
 The endocannabinoid system (ECS) regulates a multitude of obesity-
related physiological processes. These include appetite, inflammation, intestinal 
permeability and motility, etc (Azua et al., 2017; Cani et al., 2016; Cota et al., 
2003). The ECS is comprised of cannabinoid receptors and their endogenous 
lipophilic ligands called endocannabinoids. The two main cannabinoid receptors 
are the seven-transmembrane G-protein coupled receptors CB1 and CB2, 
although non-classical cannabinoid receptors include the orphan receptor 
GPR55 and transient receptor potential vanilloid type 1. CB1 expression is most 
abundant in the central nervous system but is also located at peripheral nerve 
terminals, in metabolic tissues such as the liver, adipose tissue, muscle, and 
intestines, and in some immune cells (Maccarrone et al., 2015). CB2 is mainly 
expressed in the immune system, where its activation promotes anti-
inflammatory responses (Turcotte et al., 2016). The two best-characterized 
endocannabinoids are arachidonic acid derivatives N-arachidonoylethanolamine 
(Anandamide, AEA), a high affinity, partial agonist for CB1, and 2-
arachidonylglycerol (2-AG), a moderate affinity, full agonist at both CB1 and CB2. 
Both of these endocannabinoids are produced as needed from cell membrane 
lipid precursors (Maccarrone et al., 2015). AEA is produced by the enzymes N-
acyltransferase and N-acyl-phosphatidylethanolamine-specific phospholipase D 
and broken down by mainly by fatty acid amide hydrolase (FAAH) (Maccarrone 
et al., 2015). AEA is also a precursor for various inflammatory mediators such as 
prostaglandins and leukotrienes. 2-AG is synthesized by diacylglycerol lipases 
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alpha and beta, and quickly catabolized by monoacylglycerol lipase (Maccarrone 
et al., 2015).  
 Modulation of ECS activity during obesity was recognized in the early 
2000s when it was discovered that activation of CB1 promotes over eating and 
obesity (Cota et al., 2003). Subsequent CB1 knockout and antagonist studies in 
animal models confirmed involvement of CB1 activation in promoting obesity, 
which led to testing CB1 antagonists for human obesity intervention (Ravinet 
Trillou et al., 2003, 2004). Unfortunately, adverse neuropsychiatric side effects 
caused SR141716A (also known as Rimonabant), a CB1 antagonist, to be 
removed from market (Pi-Sunyer et al., 2006; Sam et al., 2011). Despite this, 
animal studies have continued in order to identify mechanisms involved in the 
beneficial effects of CB1-blockade, some of which are presented in this 
dissertation.   
 Furthermore, circulating endocannabinoids are elevated during obesity, 
however; overactivation of CB1 by AEA is most recognized to contribute to 
excessive energy storage and appetite (Balsevich et al., 2018; Brown et al., 
2012; Engeli et al., 2005; Touriño et al., 2010). Genetic ablation of FAAH, which 
hydrolyzes AEA, promotes excessive energy storage and adiposity (Touriño et 
al., 2010). Moreover, mutations in the FAAH gene are associated with human 
obesity (Sipe et al., 2005). These observations further support the beneficial 
effects of CB1 blockade on obesity. 
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More recently the role of CB2 activation in metabolic regulation has been 
discovered. Treatment of obese mice with the CB2 agonist JWH-015 reduces fat 
mass and inflammation, which indicates that not only blocking CB1 but also 
activating CB2 has anti-obesity effects (Verty et al., 2015). Polymorphisms in the 
CB2 gene (Cnr2) also contribute to overeating disorders (Ishiguro et al., 2010). 
This demonstrates the complementary nature of cannabinoid receptor signaling 
and also indicates that some beneficial effects observed upon CB1 blockade may 
be attributed to increased endocannabinoid signaling through CB2. In this 
dissertation, data in regards to CB2 signaling in obesity are also provided. 
1.4 EPIGENETIC REGULATION 
Epigenetic regulation of gene expression is regulation independent of 
alterations in DNA sequence. It is important to note that many environmental 
factors such as diet, exercise, and stress, etc. can alter gene expression through 
epigenetic modifications without changing the underlying DNA sequence (Toraño 
et al., 2016). Therefore studying epigenetic regulation is essential to understand 
the pathophysiology of many diseases. Epigenetic mechanisms pertinent to this 
dissertation are microRNAs (miRNA, miR) and DNA methylation.  
MicroRNAs are short (~22 nucleotide long) non-coding RNAs that silence 
genes by complementary binding to the 3’ untranslated region of target genes, 
which causes translational repression or transcript degradation (Bartel, 2004). It 
is thought that ~60% of protein-coding genes are conserved targets of miRNAs 
and therefore they have emerged as important regulators of gene expression 
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(Lewis et al., 2005). Additionally, specific miRNAs have been identified as 
biomarkers and/or prognostic indicators in a variety of diseases, which 
demonstrates their importance in the field of personalized medicine and 
currently, synthetic miRNA mimics and inhibitors are being developed for clinical 
purposes (Alexander et al., 2011; Reid et al., 2016).,  
DNA methylation silences gene expression due to chromatin condensation 
(Caiafa and Zampieri, 2005). DNA methyltransferases (DNMT) add methyl 
groups to cytosine nucleotides. DNMT1 maintains DNA methylation while 
DNMT3a and DNMT3b perform de novo methylation (Jin and Robertson, 2013). 
Methylated cytosines primarily reside in CpG islands—which are genomic 
regions of enriched C-G content proximal to transcription start sites—and repress 
gene transcription by decreasing accessibility of transcription factor binding sites 
(Caiafa and Zampieri, 2005). Importantly, DNA methylation has been implicated 
in development of pathologies including atherosclerosis and cancer, and has 
been a therapeutic target for several diseases (Dong et al., 2002; Zhang et al., 
2011).  
1.5 MICROBIOTA 
 It is becoming increasingly evident that the intestinal flora is a major 
contributor to the pathophysiology of many diseases, including obesity. The gut 
microbiota is comprised of trillions of microbes that colonize the gastrointestinal 
tract and collectively contribute to metabolic processes, such as energy harvest, 
and can be thought of as a metabolic organ (Bäckhed et al., 2007). The 
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dependence on microbiota for excessive energy harvest was identified in 2004 
when it was discovered that germ-free mice fed a high-fat diet were more lean 
than conventionally raised colonized mice (Bäckhed et al., 2004). Additionally, 
conventionalization of germ-free mice led to rapid increases in weight gain 
(Bäckhed et al., 2004). More recent studies have also demonstrated that 
microbiota depletion through antibiotic administration promotes white adipose 
tissue browning, which increases energy expenditure, reduces inflammation, and 
lessens obesity (Suárez-Zamorano et al., 2015). Hence the complex interactions 
of the gut microbiota with host processes have been investigated for therapeutic 
purposes. 
 The advent of next-generation sequencing technology has allowed 
characterization of the gut microbiome, including those microbes that are difficult 
to culture and thus poorly characterized (Forde and O’Toole, 2013). Interrogation 
of the obese gut microbiome revealed that it has an increased capacity for 
energy harvest, decreased diversity, and generally an increase in the Firmicutes 
to Bacteroidetes ratio (Ley et al., 2005; Turnbaugh et al., 2006). These 
alterations in the obese microbiome can be called “dysbiosis” due to having 
detrimental effects on host health status (Petersen and Round, 2014). 
Interestingly, fecal transplantation transfers donor obesity phenotype into the 
recipient (Turnbaugh et al., 2006). Transfer of donor phenotypes in various 
disease models has made the gut microbiota a very interesting therapeutic target 
(Gupta et al., 2016). In fact, fecal microbiota transplant to promote weight loss in 
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obese people is currently in clinical trial (ClinicalTrials.gov identifier: 
NCT03789461). 
 While the association of the gut microbiota composition with obesity 
phenotype is well established, there is still much to be learned about the complex 
interactions between various microbes and the host. This will aid in developing 
better therapeutics in the future. In particular, ECS modulation of the gut 
microbiota: host interactions during obesity are presented within this dissertation.  
1.6 HYPOTHESES AND AIMS 
 Obesity is an energy imbalance disease that is characterized by 
overactivation of the ECS, chronic-low grade inflammation, and gut microbiota 
dysbiosis. CB1 blockade reverses obesity, yet the anti-inflammatory mechanisms 
involved are not well characterized. Furthermore, characterization of the gut 
microbiome: host interactions with cannabinoid receptor signaling modulation 
have not been heavily investigated. This dissertation presents three studies that 
were aimed at investigating ECS regulation of ATM-mediated inflammation and 
gut microbiota: host interactions. 
 In study one, miRNA regulation of ATM polarization was investigated in a 
mouse model of diet-induced obesity. Classification of miRNA profiles in lean and 
obese ATMs were not previously characterized. We hypothesized that the 
inflammatory polarization of ATMs could be regulated by miRNA expression.  
 In the second study, we investigated the anti-inflammatory mechanisms 
involved in attenuation of diet-induced obesity after CB1 blockade. We 
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hypothesized that decreased obesity and inflammation observed following CB1 
antagonist treatment in diet-induced obese mice was associated with altered 
miRNA profile in ATMs. 
 In the final study, gut microbiota profiles and microbiota: host interactions 
were investigated in diet-induced obese mice of wild-type, CB1-/- and CB2-/- 
genotypes, as well as in obese mice treated with the CB1 antagonist AM251. We 
hypothesized that the ECS contributes to the overall metabolic and inflammatory 
tone during obesity through alterations in gut microbiota composition/metabolism 





Figure 1.1 Epididymal adipose tissue morphology in lean and high-fat diet-
induced obese mice. 
Immunofluorescent staining of epididymal adipose tissue from lean and obese 
mice shows distinct morphological features. Lean adipose tissue is homeostatic 
with organized adipocyte structure and uniformly dispersed ATMs that maintain 
immune surveillance. Obese adipose tissue contains hypertrophic adipocytes 
and infiltrating ATMs that form crown-like structures around necrotic adipocytes. 
Tissue damage is evident. Whole mount staining of adipose tissue and confocal 
microscopy were performed as described in chapter 2, section 2. Green depicts 
Hoechst staining of cellular nuclei. Red indicates Immunofluorescent staining of 
F4/80+ macrophages. Blue represents BODIPY staining of lipids and adipocytes. 
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Background/Objectives: Obesity is a pandemic disorder that is characterized 
by accumulation of adipose tissue and chronic-low grade inflammation that is 
driven primarily by adipose tissue macrophages (ATMs). While ATM polarization 
from pro-(M1) to anti-(M2) inflammatory phenotype influences insulin sensitivity 
and energy expenditure, the mechanisms of such a switch are unclear. In the 
current study we identified epigenetic pathways including microRNAs (miR) in 
ATMs that regulate obesity-induced inflammation. 
Subjects/Methods: Male C57BL/6J mice were fed normal chow diet (NCD) or 
high-fat diet (HFD) for 16 weeks to develop lean and diet-induced obese mice 
respectively. Transcriptome microarrays, microRNA microarrays, and meDIP-
Seq were performed on ATMs isolated from visceral fat. Pathway analysis and 
bone marrow derived macrophage (BMDM) transfections further allowed 
computational and functional analysis of miRNA-mediated ATM polarization. 
Results: ATMs from HFD-fed mice were skewed towards M1 inflammatory 
phenotype. Concurrently, the expression of miRs 30a-5p, 30c-5p, and 30e-5p 
was downregulated in ATMs from HFD mice when compared to mice fed NCD.  
The miR-30 family was shown to target Delta-like-4, a Notch1 ligand, whose 
expression was increased in HFD ATMs. Inhibition of miR-30 in conditioned 
BMDM triggered Notch1 signaling, pro-inflammatory cytokine production, and M1 
macrophage polarization. In addition, DNA hypermethylation was observed in 
mir30-associated CpG islands suggesting HFD downregulates miR-30 through 
epigenetic modifications.  
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Conclusions: HFD-induced obesity downregulates miR-30 by DNA methylation 
thereby inducing Notch1 signaling in ATMs and their polarization to M1 
macrophages.  These findings identify miR-30 as a regulator of pro-inflammatory 
ATM polarization and suggest miR-30 manipulation could be a therapeutic target 
for obesity-induced inflammation. 
 
2.2 INTRODUCTION 
Overnutrition causes obesity and adipose tissue macrophage (ATM)-
dependent inflammation that enhances risk for type II diabetes, cardiovascular 
disease, and some cancers. Macrophages are innate immune cells that display 
remarkable plasticity between pro- and anti-inflammatory phenotypes.  They are 
routinely classified as M1 and M2 respectively, although various subtypes exist 
(Hamilton et al., 2014). At steady state, resident M2-like ATMs contribute to 
insulin sensitivity and adipose tissue homeostasis through production of anti-
inflammatory cytokines such as IL-10 (Boutens and Stienstra, 2016). During 
obesity, M1 ATMs dominate the adipose tissue in both phenotype and 
abundance, promoting insulin resistance and chronic low-grade inflammation 
(Lumeng et al., 2007). Due to vast disparities seen in ATM functionality between 
lean and obese individuals, ATMs have been suggested to play a substantial role 
in determining development of obesity-related pathologies. Therapeutic 
strategies that decrease ATM-dependent inflammation have been heavily 
investigated due to the tight correlation of macrophage-dependent inflammation 
and insulin resistance.  
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Notch signaling plays key roles in metabolic and inflammatory processes 
(Bi and Kuang, 2015). It is highly conserved juxtacrine signaling utilized by 
numerous cell types including macrophages and adipocytes. Binding of Notch 
receptors (Notch1-4) by Delta-like and Jagged ligands (DLL1, -3, -4 and JAG1, -
2) initiates proteolytic release of the Notch intracellular domain (NICD) allowing it 
to translocate to the nucleus and activate Jk-Recombination Signal-Binding 
Protein (RBP-J)-dependent transcription (Borggrefe and Liefke, 2012). In 
macrophages, Notch1 signaling promotes pro-inflammatory polarization through 
IRF8 and NF-kB transcriptional pathways, while in adipocytes, Notch1 signaling 
inhibits white adipose tissue browning and energy expenditure, and promotes 
insulin resistance (Bi et al., 2014; Pajvani et al., 2011; Xu et al., 2012). 
Additionally, blockade of the canonical Notch1 ligand DLL4 improves 
atherosclerosis and metabolic disease indicating DLL4-Notch1 signaling is 
directly involved in the crosstalk of inflammatory and metabolic pathways 
(Fukuda et al., 2012). 
Recent studies in our laboratory have identified epigenetic modifications 
which regulate immune responses in a variety of diseases including post-
traumatic stress disorder, multiple sclerosis, colitis, and liver failure (Bam et al., 
2016; Busbee et al., 2015; Guan et al., 2016; Singh et al., 2014). MicroRNAs 
(miRNA, miR) are short (~22 nucleotide long) non-coding RNAs that post-
transcriptionally inhibit protein translation by binding the 3’ untranslated region 
(3’UTR) of target mRNAs (Bartel, 2004). Because approximately 60% of protein-
coding genes are known conserved targets of miRNAs, they have emerged as 
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important regulators of biological functions such as immune system development 
and inflammatory responses (Lewis et al., 2005; Xiao and Rajewsky, 2009). DNA 
methylation occurs when methyl groups are added to cytosines by DNA 
methyltransferases (DNMT). These methylated cytosines primarily reside in CpG 
islands near transcription start sites and repress gene transcription by blocking 
binding sites for transcription factors through chromatin condensation. 
Importantly, DNA methylation and miRNAs have been associated with 
development of aging-associated pathologies including obesity, atherosclerosis, 
and cancer (Dong et al., 2002; Ge et al., 2014; Zhang et al., 2011). 
Numerous miRNAs have already been classified to regulate differentiation and 
function of both adipocytes and macrophages.  However, characterization of 
miRNA expression specifically in ATMs from lean and obese individuals has not 
been previously reported. Such investigation warrants merit because ATMs 
comprise a unique cell type due to their immunometabolic functions and 
dominance in the adipose tissue of obese individuals. Also, ATMs are thought to 
be the main initiators of obesity-induced inflammation and insulin resistance (Xu 
et al., 2003). In this report, we have identified dysregulated microRNAs in ATMs 
during obesity, which demonstrates that obese ATMs have distinct miRNA 
profiles that are likely to contribute to their inflammatory phenotype. Specifically, 
we discovered downregulation of the miR-30 family in ATMs to modulate 
macrophage phenotype. Our findings demonstrate that miR-30 regulates pro-
inflammatory polarization of ATMs, and is likely due to regulation of DLL4-
mediated Notch1 signaling. Our data also suggest therapeutic manipulation of 
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this miRNA family or the epigenetic mechanisms that regulate its expression, 
may constitute therapeutic modalities for obesity-induced inflammation, insulin 
resistance, and related cardiometabolic disorders. 
	
2.3  MATERIALS AND METHODS 
Mice 
6- to 8-week-old male and female C57Bl/6J mice and 22-week-old male 
C57Bl/6J mice fed either 60% kcal HFD (D12492, Research Diets), NCD (8904, 
Envigo Teklad), or purified 10% low-fat diet (LFD, D12450J, Research Diets) 
where indicated, for 16 weeks were obtained from The Jackson Laboratory and 
housed in a specific-pathogen-free facility. Studies were not blinded and mice 
were not randomized into experimental groups. At the conclusion of each study, 
mice were euthanized by overdose isoflurane inhalation. All procedures were 
performed in accordance with protocols approved by the University of South 
Carolina Institutional Animal Care and Use Committee.  
Analytical Procedures 
Body composition of lean mass, fat mass, and percent fat were measured 
by dual-energy x-ray absorptiometry (DEXA) (LUNAR PIXImus). Mice were 
placed under isoflurane anesthesia and scanned in the prone position with the 
head region being excluded. Body weight was monitored using an electronic 
gram scale with precision ± 0.1g. For glucose tolerance tests, mice underwent a 
5hr morning fast before fasting glucose measurement then gavaged with 2 g/kg 
lean mass glucose (Sigma G7528). Blood glucose was measured 15, 30, 60 and 
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120m post-glucose bolus by applying approximately 5uL tail-tip blood to a 
glucose test strip in a glucose meter (Contour Next, Bayer).  
Adipose Tissue Dissociation and ATM Isolation  
To dissociate cells of the stromal vascular fraction (SVF), epididymal fat 
pads from 22-week-old mice were dissected, rinsed in phosphate buffered saline 
(PBS) and homogenized in 5mL digestion media consisting of Hank’s Balanced 
Salt Solution (HBSS) containing 2% bovine serum albumin (BSA) and 1mg/mL 
collagenase (Sigma C6885) using a gentleMACs dissociator (Miltenyi Biotec). An 
additional 5mL digestion media was added to the homogenates and incubated 
37°C, 75 RPM, 30-40m until fully dissociated. Next, 5mL complete Dulbecco's 
Modified Eagle's Medium and Ham's F-12 Nutrient Mixture (DMEM/F12) 
containing 10% FBS and 1% penicillin/streptomycin was added to the samples 
before filtering through a 100um nylon mesh. SVF cells were pelleted (1200 
RPM, 4°C, 10m), RBC-lysed, filtered through a 70um nylon mesh and washed in 
complete DMEM/F12 then used immediately for desired application. To purify 
ATMs, SFV cells were washed twice in FACS buffer consisting of PBS, 2% heat-
inactivated fetal bovine serum (FBS), and 1mM EDTA then incubated in FcR-
Blocker (StemCell Tech, 18720) followed by PE-conjugated anti-F4/80 
(BioLegend, Clone BM8). F4/80+ cells were immunomagnetically selected by 
EasySep PE positive selection kit according to manufacturer protocol including 4 
total wash steps (StemCell Tech, 18557). Flow cytometry was used to verify 




RNA Purification, cDNA Synthesis, and quantitative RT-PCR  
ATMs were lysed in Qiazol and total RNA was purified using Qiagen 
miRNeasy Micro kit. RNA concentration and purity was measured using a 
NanoDrop 2000 spectrophotometer. 400ng total RNA was reverse transcribed to 
cDNA using Qiagen miScript II RT kit with HiFlex buffer. To validate miRNA 
expression by qRT-PCR, miScript SYBR Green PCR kit and miScript miRNA 
Primer Assays were used (Qiagen).  
ATM MicroRNA and Transcriptome Microarrays  
MicroRNA and transcriptome microarrays were performed using 3 
biological replicates of total RNA isolated from pools of ATMs (NCD: pools of 20 
mice, HFD: pools of 10 mice). For each miRNA microarray, 500 ng total RNA 
was polyadenylated then labeled using the Affymetrix FlashTag Biotin HSR RNA 
Labeling Kit. Labeled samples were hybridized to Affymetrix miRNA 4.0 chips 
overnight (16 h, 48°C, 60 RPM) then washed, stained, and scanned on an 
Affymetrix GCS 3000 system following manufacturer protocols. For transcriptome 
microarrays, 100ng total RNA was used as starting material. RNA was prepared 
for hybridization by using the Affymetrix GeneChip WT PLUS Reagent Kit 
according to manufacturer protocol. Labeled samples were hybridized to MTA 
1.0 chips overnight (16h, 45°C, 60 RPM) then washed, stained, and scanned on 
an Affymetrix GCS 3000 system. Affymetrix Expression Console Version 1.4.1.46 
was used for quality control, data summarization, and normalization. Affymetrix 
Transcriptome Analysis Console Version 3.1.0.5 was used to perform differential 
expression analyses. Transcripts or miRNAs were considered differentially 
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expressed between the two groups if linear fold change was greater than ±2 and 
the ANOVA p-value was less than 0.05. Heatmap figures of differentially 
expressed microRNAs and mRNAs were made using Genesis Version 
1.7.7.(Sturn et al., 2002)  
Immunofluorescence 
Epididymal fat was dissected, minced (~3mm x 3mm), washed in PBS, 
and then fixed in 4% paraformaldehyde for 3h.  Fixed tissues were permeabilized 
with 1% Triton X-100 for 10 min then blocked with 1% BSA and FcR-Blocker for 
1h at RT. Samples were incubated with primary antibody (BioLegend: anti-F4/80-
AlexaFluor488 clone: BM8, and anti-Notch1 clone: HMN1-12, or anti-DLL4 clone: 
HMD4-1) overnight at 4°C, then incubated with anti- Hamster IgG-AlexaFluor633 
secondary antibody for 1h at RT (Invitrogen SA1-26817, Molecular Probes 
labeling kit A20170). Tissues were counterstained with 40uM Hoechst 33342 and 
5uM BODIPY 558/568 C12 (Molecular Probes H21492 & D3835) for 1h at RT 
then washed and mounted on slides using a Vaseline boundary and 
Fluoromount-G (eBioscience, 00-4958-02). 
Confocal Microscopy and Image Analysis 
Confocal images of whole-mount adipose tissue were acquired on a Zeiss 
LSM 510 Meta Confocal Scanning Laser Microscope equipped with UV, Argon, 
green HeNe and red HeNe lasers. 5 random images per sample were taken 
using a 40X water immersion objective. Original .lsm files were imported into Fiji 
(Fiji Is Just ImageJ, NIH) then split into channels. Thresholds were applied to the 
Cy5 channel using Fiji’s max Entropy algorithm to identify regions of interest 
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(ROIs) that express either Notch1 or DLL4. Area and intensity (mean gray value) 
were measured for each ROI. The product of positive signal area and intensity 
were used to determine total expression per image. Each biological replicate is 
the mean expression of 5 images. We then divided the expression values for 
each biological replicate by the mean of the NCD biological replicates. Therefore, 
data are presented as fold expression in arbitrary units (AU) with mean NCD set 
as control. 
Flow Cytometry 
Freshly isolated SVF cells or cultured BMDM were washed in FACS buffer 
then incubated on ice with FcR-Blocker for 10m followed by appropriate 
fluorochrome-conjugated antibodies or isotype controls (BioLegend, anti-CD11b-
AlexaFluor488 clone: M1/70, anti-F4/80-PE clone: BM8, anti-DLL4-APC clone: 
HMD4-1, anti-CD45-PECy7 clone: 30-F11, anti-CD11c-APC clone: N418) for 
50m. Stained cells were washed 3X in FACS buffer then analyzed on a Beckman 
Coulter FC500 or BD FACSCelesta flow cytometer. Plots were analyzed with 
Beckman Coulter CXP Software or FlowJo v10. 
In Vitro Locked Nucleic Acid (LNA) Transfection Assays 
Bone marrow derived macrophages (BMDM) were differentiated from 
bone marrow cells (BMC) by flushing the tibia and femur of 6-8 week old female 
C57Bl/6J mice with PBS. BMCs were filtered through a 70um nylon mesh, RBC-
lysed, and washed, then cultured in complete DMEM/F12 supplemented with 
10% FBS, 1% penicillin/streptomycin, 2mM L-glutamine, and 1U/mL M-CSF 
(BioLegend, 576406) for 7-10 days. 3T3-L1 adipocyte-conditioned media (CM-
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3T3-L1A) was generated by differentiating 3T3-L1 preadipocytes into adipocytes 
according to the Zen-Bio 3T3-L1 Adipocyte Care Manual (ZBM0009.03). 
Preadipocyte medium, differentiation medium, and adipocyte maintenance 
medium were also used (Zen-Bio, PM-1-L1, DM-2-L1, AM-1-L1). Conditioned 
medium was collected between days 7 and 14 post-differentiation, 0.22um 
filtered, aliquoted, and stored at -80°C until use. For transfection assays, mature 
BMDM were plated in poly-D-lysine-coated 6-well plates at a density of 5x105 
cells in 2ml CM-3T3-L1A containing 10% FBS without antibiotics. BMDM were 
incubated 24h (37°C, 5% CO2, 95% humidity) before transfection. Transfection 
complexes were prepared by diluting Lipofectamine3000 and LNA in Opti-MEM 
to final concentrations of 2% (v/v) and 0.32mM respectively. Mixtures were 
incubated 15-20m at RT to allow complexes to form. Meanwhile, conditioned 
BMDM were washed 3X in pre-warmed Dulbecco’s PBS (DPBS), then media 
replaced with 2mL Opti-MEM. 500uL transfection complexes were added drop-
wise to each well. Cells were incubated (37°C, 5% CO2, 95% humidity) 5-6hr to 
allow LNA uptake, washed 3X in pre-warmed DPBS, then media replaced with 
DMEM/F12 containing 10%FBS, 1% penicillin/streptomycin, and 2mM L-
glutamine, and cultured for an additional 18h. For inhibition studies, DAPT (5uM), 
anti-DLL4 antibody (1ug/mL), or appropriate vehicle/isotype antibody controls 
were added to the culture media.  MirCURY LNA oligonucleotides were obtained 
from Exiqon. (LNA Sequences— Ctr LNA: TAA CAC GTC TAT ACG CCC A, 
Anti-30a: TTC CAG TCG AGG ATG TTT AC, Anti-30c: CTG AGA GTG TAG 
GAT GTT, Anti-30e: TCC AGT CAA GGA TGT TTA C). 
	
24 
Protein Extraction and Western Blotting 
Cultured BMDM were washed twice in ice-cold PBS, and then directly 
scrapped into 100uL blue loading buffer (Cell Signaling Tech 7722) and kept on 
ice. Protein lysates were sonicated 10s then heated at 95°C for 5m before 
loading 20uL on Mini-Protean TGX Protein Gels (BioRad 4569034). Precision 
Plus Protein Dual Color Standards (BioRad 1610374) were loaded for a 
molecular weight ladder. Samples were run 40V for 30 min followed by 80V for 
1.5h. Proteins were transferred to nitrocellulose membranes by using iBlot 2 NC 
stacks and the ThermoFisher iBlot 2 western transfer system running the P0 
protocol (20V 1m, 23V 4m, then 25V 2m). Membranes were blocked in 5% dry 
milk or 5% BSA for 1h then washed 3X in Tris-buffered saline containing 0.1% 
Tween-20 (TBS-T). Membranes were incubated in primary antibody overnight at 
4°C with gentle shaking then washed 3 x 5m in TBS-T. Membranes were 
incubated in secondary antibody for 1h at RT, then washed 3 x 5m in TBS-T 
before addition of ECL substrate and exposure to x-ray film. Films were scanned 
and densitometry measurements were made using ImageJ gel analysis features 
(NIH).  
Enzyme-linked Immunosorbent Assays (ELISA) 
Culture supernatants were aspirated and centrifuged 5000 RPM, 5m, 4°C 
to rid of debris then aliquoted and stored -80°C before assaying. DLL4 ELISA kits 
were purchased from Abcam (ab213860). Mouse TNFα and CCL2 ELISA kits 
were purchased from BioLegend (TNFα 530901 & CCL2 432701). Assays were 
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performed according to manufacturer protocols and plates were read at 450nm. 
Concentrations were calculated using standard curves.  
Methylated DNA Immunoprecipitation Sequencing (MeDIP-seq) 
MeDIP-seq libraries were generated from ATM DNA as previously 
described and sequenced with single-end reads of 75bp on an Illumina 
NextSeq500 (Bam et al., 2015). Data analysis was performed as previously 
described (Bam et al., 2015). Mapped reads were analyzed using MEDIPS 
software (Lienhard et al., 2014). Peaks were visualized in the Integrated Genome 
Browser (Freese et al., 2016). The UCSC genome browser was used to locate 
CpG islands within 10kb of miR-30 gene coding regions (Kent et al., 2002). 
Methylation-specific PCR 
Genomic DNA from NCD and HFD ATMs were isolated using Qiagen 
AllPrep DNA/RNA/miRNA Universal Kit (80224). Bisulfite conversion of DNA was 
performed using Qiagen EpiTect Fast DNA Bisulfite Kit (59824). PCR using 
methylated and unmethylated primers specific for the Nfyc CpG island 
(Methylated: Fwd—TTC GTT AAT GGG AGA AAG TTC  Rev—CTA CCG CCG 
CCA TAT TAT A  Unmethylated: Fwd—TTT TTT GTT AAT GGG AGA AAG TTT, 
Rev—ACT CTA CCA CCA CCA TAT TAT A). Primers were designed using 
ThermoFisher Methyl Primer Express Software v1.0. BioRad iQ SYBR Green 
Supermix was used and qRT-PCR was run using the following reaction 
conditions: initial denaturation- 95°C 5m followed by 31 cycles of- 95°C 15s, 
49.8°C 30s, and 70°C 35s.  PCR products were run on a 1.5% agarose gel and 
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bands were quantified using FIJI gel analysis features. Methylation ratio was 
determined by dividing methylated by unmethylated quantities (M/U). 
Lentiviral Overexpression of miR-30a-5p in the RAW264.7 macrophage cell line 
MicroRNA lentiviral expression vectors were purchased from Applied 
Biological Materials (ABM) (Cat No. m001 and mm10332) and then amplified in 
DH5α competent cells. Amplified plasmid DNA was isolated using Qiagen 
EndoFree Plasmid Maxi Kit. Lentiviruses were produced in HEK293T cells using 
ABM’s 3rd generation packaging mix and Lentifection transfection reagent (Cat 
no. LV053 and G074). Lentiviruses were collected from the culture supernatant 
and cellular debris was pelleted by centrifugation at 3000 rpm for 15 min at 4°C. 
The cleared supernatant was filtered through a 0.45um PVDF sterile filter. The 
viral titer was determined by ABM qPCR titration kit (Cat no. LV900-S). Lentivirus 
aliquots were stored at -80°C. RAW264.7 target cells were transduced with 
lentivirus at a multiplicity of infection of 2.5. 48hr following transduction, culture 
supernatants were collected for TNFα and CCL2 ELISAs and the cells were 
stained for flow cytometry. 
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism Version 7.000 
for Mac, GraphPad Software, La Jolla California USA, www.graphpad.com. 
Values are expressed as mean ± standard error. Two-tailed Student’s t tests 
were performed for paired analyses. One-way ANOVA with a Bonferroni post hoc 
correction were used for multiple group analyses. The null hypothesis was 
rejected if p<0.05. All experiments were repeated at least twice, unless otherwise 
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indicated in each figure legend. Detailed sample sizes are provided in each figure 
legend. Sample sizes were chosen by power analysis based on pilot studies. 
 
2.4 RESULTS 
Obesity Promotes ATM miRNA Dysregulation and Pro-Inflammatory Phenotype 
To study ATMs associated with obesity (will be referred to as obese 
ATMs), we used a high-fat diet (HFD)-induced obesity model whereby 6-week-
old male C57BL/6J mice were fed HFD or normal chow diet (NCD) for 16 weeks 
to generate diet-induced obese and lean control mice. HFD-fed mice more than 
doubled their body weight during 16 weeks of feeding whereas NCD-fed mice 
increased their weight by ~3% (Figures 2.1A-2.1C), and HFD-induced weight 
gain occurred due to selective increases in fat mass (Figure 2.1C). As expected, 
HFD also caused glucose intolerance measured by glucose tolerance test (GTT) 
(Figures 2.1D and 2.1E).  
While phenotyping ATMs, we observed percentages of ATMs 
(F4/80+/CD11b+) and CD11c+ ATMs in epididymal fat of obese mice were more 
than 2 and 4 fold that of lean mice respectively (Figure 2.1F and 2.1G). To 
identify gene expression alterations in HFD and NCD ATMs we performed 
transcriptome microarrays using F4/80+ cells from epididymal fat of HFD and 
NCD mice.  Principal component analysis (PCA) displayed HFD and NCD ATMs 
have distinct transcript expression profiles (Figure 2.2A). HFD ATMs exhibited 
increased M1- and decreased M2-associated gene expression (Figure 2.1H and 
Table 2.1). Notably, Irf8, which encodes a transcription factor activated by Notch-
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RBPJ signaling, as well as Itgax, which encodes the M1 surface marker CD11c, 
were upregulated in obese ATMs (Lumeng et al., 2007; Xu et al., 2012). 
Alternatively, Klf4, which encodes Krüppel-like factor 4 that cooperates with 
STAT6 to promote M2 polarization, and Adipor2, which encodes a receptor for 
the anti-inflammatory adipokine adiponectin, were downregulated in obese ATMs 
(Liao et al., 2011; van Stijn et al., 2015). Together these observations suggested 
that HFD ATM phenotype was skewed towards M1.  
To identify differentially expressed miRNAs in ATMs during obesity, we 
performed miRNA microarrays using F4/80+ cells isolated from epididymal fat of 
HFD and NCD mice. PCA showed HFD and NCD ATMs have distinct miRNA 
expression profiles (Figure 2.2B). In total, there were 37 down- and 12 up-
regulated miRNAs in HFD versus NCD ATMs (Figures 2.1I, 2.1J and Table 2.1). 
Additionally, transcriptome microarrays showed there were 946 down- and 920 
up-regulated transcripts in HFD versus NCD ATMs. Of these, 216 and 273 
coding genes were up- and down-regulated respectively (Figure 2.2C).  We 
performed core analysis on these dysregulated miRNAs and transcripts using 
Ingenuity Pathway Analysis and observed significant overlap with canonical 
pathways including hepatic fibrosis and atherosclerosis signaling, disorders such 
as cancer and hepatic disease, cellular functions including movement and 
survival, and toxic effects including cardiotoxicity, hepatotoxicity, and 
nephrotoxicity (Figures 2.2D-2.2H). 
Upon closer examination of dysregulated miRNAs during obesity, we 
observed downregulation of miR-322-5p (-17.1 linear FC) and miR-155-5p (-
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14.19 linear FC), which have been previously characterized for their involvement 
in macrophage functions (O’Connell et al., 2007; Zhang et al., 2017). 
Interestingly, we also noted downregulation of miRs -30a-5p, -30c-5p, and -30e-
5p in HFD ATMs (-12.27 combined linear FC) when compared to NCD ATMs, 
thereby indicating that the miR-30 family may play a role in macrophage 
polarization (Figures 2.1I-2.1M).  
The miR-30 target DLL4 is associated with ATM inflammation 
When we looked at potential target molecules for miR-30, we found 
through in silico analyses that it may target the 3’UTR of Dll4 (Figures 2.3A-
2.3C).  Previous studies had confirmed miR-30-Dll4 targeting using luciferase 
reporter assay (Bridge et al., 2012; Shan et al., 2016). Interestingly, DLL4 has 
been shown to be involved in Notch signaling (Fukuda et al., 2012; Fung et al., 
2007; Nakano et al., 2016).  To that end, we evaluated expression of Notch1 and 
the miR-30 target DLL4 in adipose tissue. Notch1 and DLL4 were visualized in 
whole-mounted epididymal fat by confocal microscopy (Figures 2.4A and 2.4C). 
Adipose tissue expression of DLL4 but not Notch1 was elevated in HFD-fed mice 
(Figures 2.4B and 2.4D). Flow cytometry analysis of epididymal fat stromal 
vascular fractions (SVF) was then used to confirm that DLL4 expression was 
elevated on ATMs (CD45+/CD11b+/F4/80+/DLL4+) (Figures 2.4E and 2.4F). 
Specifically, elevated DLL4 expression was most pronounced in the 





MiR-30 Inhibition Promotes DLL4-Notch Signaling-Induced Inflammation in 
Macrophages 
To further demonstrate involvement of miR-30 in regulation of DLL4-
mediated Notch signaling and pro-inflammatory response in macrophages, we 
developed an in vitro assay to mimic the downregulated miR-30 expression 
observed in vivo in obese ATMs. To that end, naïve bone marrow derived 
macrophages (BMDM) were cultured in conditioned medium from differentiated 
3T3-L1 adipocytes (CM-3T3-L1A) to confer an ATM-like phenotype, and then 
transfected with miRNA inhibitor locked nucleic acids (LNA) which targeted miRs-
30a-5p (Anti-30a), -30c-5p (Anti-30c), and -30e-5p (Anti-30e) (Figure 2.5A). 
BMDM transfected with Anti-30a, Anti-30c, and Anti-30e LNAs had decreased 
expression of miRs -30a-5p, -30c-5p, and -30e-5p relative to Mock and control 
LNA (Ctr LNA)-transfected controls, although the inhibitors displayed some 
cross-reactivity (Figure 2.6).  Anti-30a, Anti-30c, and Anti-30e transfection 
increased DLL4 and activated Notch1 intracellular domain (N1ICD) expression 
compared to Mock and Ctr LNA (Figures 2.5B and 2.5C). Pro-inflammatory 
cytokines TNFα and CCL2 were also elevated in culture supernatants of inhibitor-
transfected cells (Figures 2.5D and 2.5E). Moreover, miR-30 inhibitors promoted 
increased surface expression of CD11c (Figures 2.5F and 2.5G). Treatment of 
transfected cells with the Notch/γ-secretase inhibitor DAPT reduced induction of 
CD11c in miR-30 inhibitor-transfected cells (Figures 2.7A and 2.7B). Specific 
blockade of DLL4 signaling using anti-DLL4 antibody also reduced induction of 
pro-inflammatory cytokines TNFα and CCL2 in miR-30 inhibitor-transfected cells 
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(Figures 2.7C and 2.7D). Conversely, lentiviral overexpression of miR-30a-5p in 
the RAW264.7 macrophage cell line reduced M1 polarization evidenced by 
decreased expression of CD11c and decreased TNFα and CCL2 production 
(Figure 2.8). Together these data demonstrated that miR-30 plays an anti-
inflammatory role in macrophages by regulating DLL4-Notch1 signaling, M1 
polarization and pro-inflammatory cytokine production in macrophages. 
Evidence for DNA Methylation-Dependent Regulation of miR-30 
Epigenetic modifications can occur due to various environmental factors 
such as stress, aging, and diet. Because this study involved diet-induced obesity, 
we investigated epigenetic mechanisms that may control miR-30 expression in 
ATMs. Data from transcriptome microarrays enriched for epigenetic modification 
enzymes and factors revealed that gene expression of Dnmt1 and Dnmt3a were 
upregulated in ATMs of HFD vs. NCD-fed mice (Figure 2.9A). Therefore, we 
investigated DNA methylation intensity of miR-30 gene regions. Mir30c-1 and 
mir30e are located within the same intron of the Nfyc gene, which contains a 
CpG island in it’s promoter region. Mir30a and mir30c-2 are intergenic miRNA 
genes that do not have any nearby CpG islands, therefore we were not able to 
identify DNA methylation as a potential epigenetic mechanism regulating their 
expression. We performed methylated-DNA immunoprecipitation sequencing 
(MeDIP-seq) to screen genome-wide DNA methylation in ATMs and found DNA 
hypermethylation in the Nfyc-promoter CpG island in HFD- versus LFD-ATMs 
indicating expression of miRs -30c and -30e may be regulated by DNA 
methylation. This was validated in NCD- and HFD- ATMs by methylation-specific 
	
32 
PCR (Figure 2.9C). Together, these data indicated DNA methylation-dependent 
downregulation of miR-30 may promote pro-inflammatory polarization of adipose 
tissue macrophages during obesity (Figure 2.10). 
 
2.5 DISCUSSION 
There is a clear association between pro-inflammatory ATM polarization 
and insulin resistance during HFD-induced obesity.  However, miRNA-mediated 
epigenetic mechanisms regulating ATM phenotype have not been well 
characterized.  Our results unveil a role for the miR-30 family in modulating 
polarization of macrophages in visceral adipose tissue through regulation of the 
Notch1 ligand DLL4. Furthermore, we identified that DNA methylation may play a 
role in attenuating miR-30 expression. Jointly, these findings suggest important 
roles for miRNAs and DNA methylation in regulation of ATM polarization and 
obesity-induced insulin resistance. 
DLL4 is a canonical Notch1 ligand that is linked to macrophage 
inflammation and metabolic disorders. DLL4 promotes M1 macrophage 
polarization (Fung et al., 2007; Nakano et al., 2016). Blockade of DLL4 by 
administration of anti-DLL4 antibody in mice attenuates atherosclerosis and 
metabolic disease by decreasing macrophage infiltration and inflammatory 
response (Fukuda et al., 2012). Interestingly, Notch signaling is also linked to 
insulin resistance (Bi et al., 2014; Pajvani et al., 2011). Conditional knockout of 
Notch1 or its downstream transcription factor RBP-J in adipocytes ameliorates 
obesity and insulin resistance by promoting white adipose tissue browning and 
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energy expenditure in mice (Bi et al., 2014). These findings suggest that 
downregulation of the DLL4-Notch1 axis may hold significant therapeutic 
potential for various inflammatory and metabolic disorders. Furthermore, 
identification of regulatory mechanisms controlling this pathway could reveal 
therapeutic targets for cardiometabolic disorders. In the current study, we 
identified epigenetic regulatory mechanisms of this pathway in ATMs.  
Growing bodies of evidence suggest miRNA dysregulation and aberrant 
DNA methylation play pathogenic roles in clinical disorders such as type II 
diabetes, atherosclerosis, and cancer. Inflammation is many times the underlying 
cause for these chronic diseases, and macrophages are key mediators of 
chronic-inflammation. Additionally, obesity is well known to greatly increase risk 
for these diseases. Because ATMs are a primary source of pro-inflammatory 
cytokines that initiate chronic sub-clinical inflammation during obesity, ATMs 
contribute to progression towards comorbid diseases. In the current study, we 
observed increased infiltration and pro-inflammatory polarization of macrophages 
in visceral adipose tissue. When we performed core analysis of dysregulated 
miRNAs and transcripts in ATMs during diet-induced obesity, we found 
significant overlap with cardiometabolic disease processes and cancer, which 
suggests that ATM-inflammation is tightly linked to the development of comorbid 
diseases.  
Recent reports have linked specific miRNAs to obesity as well as 
macrophage polarization. In the context of obesity, expression profiles of human 
adipose tissue have identified miRNAs such as miR-132 and miR-17-5p to be 
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involved in regulation of adipocyte growth and insulin resistance (Klöting et al., 
2009). In macrophage polarization, miR-146a and miR-155-5p are classified to 
be negative regulators of inflammatory responses to the bacterial endotoxin 
lipopolysaccharide (Taganov et al., 2006). MicroRNA expression profiles of 
whole adipose tissue and in vitro polarized macrophages have been previously 
reported, however dysregulated miRNAs between lean and obese ATMs have 
not been characterized (Ge et al., 2014; Klöting et al., 2009; Zhang et al., 2013). 
ATMs form heterogenous populations and their inflammatory status greatly 
influences adipose insulin sensitivity.  In the current study, the miRNAs that 
exhibited the most significant fold change in ATMs were miR-322-5p and miR-
155-5p. miR-322-5p is well characterized to inhibit pro-inflammatory cytokine 
production in macrophages, while miR-155-5p is also known to be involved in a 
variety of macrophage processes (O’Connell et al., 2007; Zhang et al., 2017). 
Most strikingly, we observed downregulation of several miR-30 family miRNAs in 
ATMs during obesity, yet this miR family has not been previously investigated for 
its role regulating macrophage phenotype. The miR-30 family is highly conserved 
and known to target the Notch1 ligand DLL4, which is a ligand that contributes to 
metabolic disease and macrophage inflammation (Bridge et al., 2012; Fukuda 
and Aikawa, 2013; Fukuda et al., 2012; Fung et al., 2007; Nakano et al., 2016; 
Shan et al., 2016). We observed upregulation of DLL4 on obese ATMs. 
Moreover, inhibiting miR-30 in vitro triggered DLL4-Notch1 signaling and pro-
inflammatory response in macrophages, and blocking DLL4-Notch1 signaling 
could lessen this effect. Overexpression of miR-30a-5p also decreased M1 
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polarization in the RAW264.7 macrophage cell line. Thus, we have observed that 
miR-30 is involved in attenuating M1 macrophage activation through regulation of 
the DLL4-Notch signaling pathway. These data suggest that miR-30 induction 
holds therapeutic potential for regulating macrophage-driven inflammatory and 
metabolic disorders. Furthermore, regulatory mechanisms of the miR-30 family 
warrant further investigation due to emerging advances in epigenetic therapies 
and targeted personalized medicine.   
To investigate the mechanisms through which obesity downregulates miR-
30 in ATMs, we focused on epigenetic regulation.  We observed elevated 
expression of DNMTs and DNA hypermethylation in miR-30-associated CpG 
islands in obese vs. lean ATMs. Thus, HFD may trigger DNA hypermethylation of 
miR-30 genes leading to downregulation of miR-30 to allow increased expression 
of DLL4 and Notch signaling-induced inflammation and insulin resistance during 
obesity. Our findings are summarized as an illustrative summary in Figure 2.10. 
Previous studies have suggested that miR-30 induction has metabolic 
benefits. MicroRNA-30c attenuates hyperlipidemia, hypercholesterolemia, and 
atherosclerosis in mice, while miR-30b/c promotes thermogenesis and white 
adipose tissue browning (Hu et al., 2015; Irani et al., 2016; Soh et al., 2013). 
These findings suggest that in vivo manipulation of the miR-30 family holds 
promise for therapeutic intervention of obesity-related disorders. Additionally, 
macrophage polarization plays key roles in regulation of both brown adipose 
tissue metabolism and inflammation during atherosclerosis, yet macrophage 
phenotype was not assessed in the aforementioned studies (Moore et al., 2013; 
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Qiu et al., 2014; Rao et al., 2014). Our data suggest that macrophage-specific 
miR-30 regulates polarization towards inflammatory phenotype and progression 
of chronic macrophage-driven inflammatory disorders. Thus, future studies 
targeting macrophage-specific miR-30 in vivo could shed new light on 
mechanistic and therapeutic potential of this miR family in attenuating obesity 
and other metabolic disorders. 
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Table 2.1 Dysregulated miRNAs and macrophage polarization genes 














mmu-miR-221-3p 2.54 0.00007  mmu-miR-199a-3p -2.47 0.040407 
mmu-miR-222-3p 3.19 0.000424  mmu-miR-199b-3p -2.47 0.040407 
mmu-miR-714 3.23 0.000954  mmu-let-7b-5p -3.6 0.042523 
mmu-miR-6240 2.69 0.001063  mmu-miR-195a-5p -5.2 0.043074 
mmu-miR-342-3p 2.21 0.004268  mmu-miR-29c-3p -2.45 0.043942 
mmu-miR-2137 2.02 0.018981  mmu-let-7f-5p -2.05 0.04436 
mmu-miR-1895 2.45 0.021364  mmu-miR-320-3p -2.24 0.044977 
mmu-miR-494-3p 2.23 0.022023  mmu-miR-203-3p -6.67 0.045282 
mmu-miR-1894-5p 2.76 0.025895  mmu-miR-6971-5p -2.15 0.048055 
mmu-miR-6906-5p 3.47 0.035544  mmu-miR-152-3p -2.62 0.049714 
mmu-miR-7088-5p 2.09 0.037997  Gsn  2.12 9.56E-07 
mmu-miR-668-5p 3.06 0.04592  Itgax  3.99 0.002376 
mmu-miR-7036-5p -3.07 0.000096  Irf8  2.39 0.007543 
mmu-miR-15a-3p -2.26 0.002774  Il1rn  3.73 0.007581 
mmu-miR-145a-5p -8.58 0.003083  Pak1  3.83 0.007639 
mmu-miR-150-5p -4.02 0.00323  Mmp12  2.43 0.008177 
mmu-miR-30a-3p -13 0.004316  Ccr3  2.01 0.009267 
mmu-miR-143-3p -12.28 0.004959  Ifngr1  2.17 0.033921 
mmu-miR-210-3p -2.7 0.008072  Cd44  2.39 0.040322 
mmu-miR-511-3p -2.87 0.010394  Ccr5  2.4 0.040445 
mmu-miR-7069-5p -2.94 0.012634  Ccr5  2.4 0.040445 
mmu-miR-155-5p -14.19 0.013576  Cd209f  -16.43 0.000237 
mmu-miR-3473f -2.79 0.014766  Cd209d  -21.07 0.000383 
mmu-let-7e-5p -3.21 0.017401  Cd209b  -10.21 0.000414 
mmu-miR-100-5p -7.38 0.018074  Klf4  -5.52 0.000488 
mmu-miR-669m-5p -4.26 0.022299  Cd209e  -2.69 0.001121 
mmu-miR-466m-5p -4.26 0.022299  Cd209a  -8.22 0.001402 
mmu-miR-200c-3p -6.1 0.024927  Mtus1  -2.1 0.003759 
mmu-miR-30e-5p -3.65 0.026714  Cd209c  -4.38 0.005042 
mmu-miR-322-5p -17.1 0.029387  Adipor2  -2.06 0.01107 
mmu-miR-30a-5p -5.22 0.03013  Mmp9  -8.58 0.012721 
mmu-miR-143-5p -2.61 0.030279  Nt5e  -2.13 0.01318 
mmu-miR-1934-3p -2.34 0.030372  Csf1  -2.89 0.01473 
mmu-miR-138-5p -7.82 0.031309  Junb  -3.04 0.01674 
mmu-miR-30c-5p -3.4 0.031619  Icam1  -2.42 0.021615 
mmu-miR-671-5p -2.42 0.033095  Cav1  -3.47 0.028567 
mmu-miR-192-5p -5.91 0.033668  Chil3  -2.75 0.044279 
mmu-miR-700-3p -2.19 0.037904  S1pr1  -4.61 0.047906 





Figure 2.1 HFD-Induced Obesity Stimulates ATM Inflammation and miRNA 
Dysregulation.  
To study HFD-induced obesity, male C57BL/6J mice were fed NCD or HFD for 
16 weeks until 22-weeks-old. (A) Representative photo of mice after 16 weeks of 
NCD or HFD feeding. (B) Weekly measurements of body weight growth.  (C) 
DEXA body composition after 16 weeks of diet.  (D) Oral glucose tolerance test 
(GTT) after 16 weeks of diet. (E) Area under the curve (A.U.C.) for GTT. 
Represented are A.U.C. above baseline (ABV BL) or total A.U.C. (F) Flow 
cytometry dot plots of F4/80+/CD11b+/CD11c+ ATMs in the epididymal fat stromal 
vascular fraction (SVF) of NCD- or HFD-fed mice. (G) Fold percentage increase 
quantification of F4/80+/CD11b+ cells in the SVF (denoted as “ATMs”) and 
CD11c+ ATMs. Lean mice were fed either NCD or 10% low-fat diet (LFD). Obese 
mice were fed 60% HFD. (H-J) Pooled F4/80+ ATMs from epididymal fat were 
used for transcriptome and miRNA microarrays. (H) Transcriptome microarray 
heatmap of differentially expressed mRNAs in ATMs related to macrophage 
polarization. (I) MicroRNA heatmap of differentially expressed miRNAs in ATMs. 
(J) MicroRNA array volcano plot depicting linear fold change (FC) vs. ANOVA p-
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value significance. (K-M) qRT-PCR expression validation of miRs 30a-5p, 30c-
5p, and 30e-5p. For (A-F), the values are shown as mean ± SEM and are from a 
single experiment representative of at least 3 independent experiments with 5 
mice per experimental group. For (G) data shown as mean ± SEM of 4 
independent experiments with 5 mice per experimental group. For (H-M), the 
data shown are mean ± SEM and are from 3-4 independent experiments with 20 
pooled NCD mice and 10 pooled HFD mice per experiment. Statistical 






Figure 2.2 HFD-Induced Obesity Elicits Distinct Transcript and miRNA 
Expression Profiles in ATMs.  
As described in Figure 2.1 legend, F4/80+ ATMs were isolated from 22-week-old 
HFD and NCD mice and used for miRNA and transcriptome microarrays. (A) 
PCA plot of ATM transcriptome microarray signal. NCD and HFD ATMs cluster 
distinctly. (B) PCA plot of ATM microRNA microarray signal. NCD and HFD 
ATMs form distinct clusters. (C) Volcano plot of differentially expressed 
transcripts. (D-H) Ingenuity Pathway Analysis (IPA) was used to perform a core 
analysis on dysregulated transcripts and miRNAs observed in HFD ATMs. (D) 
The top associated canonical pathways are presented with their overlap ratio and 
p-values. (E) Network of overlapping canonical pathways. P-values for each 
canonical pathway are presented under each node. (F-H) The top diseases and 
bio functions (F), molecular and cellular functions (G), and toxicological functions 
(H) are presented with their number of associated molecules observed to be 
dysregulated in HFD ATMs. The data shown are representative of 3 independent 




Figure 2.3 MicroRNA-30 targets the Dll4 3’UTR.  
As shown in Figures 2.1 and 2.4, miR-30 expression is down and DLL4 is up in 
HFD versus NCD ATMs. miR-30 target pairing predictions were explored using 
online databases and pathway analysis. (A) Targetscan.com seed sequence 
alignment of miRs -30a-5p, -30c-5p, and -30e-5p with the Dll4 3’UTR. (B) IPA 
network of dysregulated miRNAs in HFD ATMs and predicted of Notch signaling 
gene targets. miR-30 and miR-322-5p had the highest negative FC values of 






Figure 2.4 DLL4 Expression is Elevated in Obese ATMs.  
HFD-induced obesity was studied as described in Figure 2.1 legend. At 22-
weeks-old, visceral adipose tissue and adipose SVF were analyzed for DLL4 
expression.  (A&C) Immunofluorescent staining of whole-mount epididymal fat. 
Scale bar = 20 µm. Presented are representative confocal micrographs of Notch1 
(A) or DLL4 (C). (B&D) Image quantification of Notch1 (B) or DLL4 (D) in adipose 
tissue. The values are shown as mean ± SEM and are from a single experiment 
representative of 2 independent experiments with 5 mice per experimental group. 
(E) Flow cytometry dot plots of DLL4+ ATMs in epididymal fat. CD11bint are 
denoted as infiltrating (“Inf”) and CD11bhi are denoted as resident (“Res”). (F) 
Quantification of DLL4+ ATM cell counts represented per mouse and per gram 
fat. Values are presented as mean ± SEM and are from a single experiment 
representative of 2 independent experiments with 4 biological replicates (pools of 
1-6 mice) per experimental group. Statistical significance was determined by 
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Figure 2.5 miR-30 Inhibition Induces DLL4-Notch1 Signaling and M1 
polarization.  
BMDM were differentiated from the bone marrow of normal mice then used to 
study in vitro consequences of miR-30 inhibition on Notch signaling and 
macrophage polarization. (A) Schematic of in vitro experimental timeline. 
Differentiated BMDM were incubated in CM-3T3-L1A prior to transfection with 
microRNA inhibitor LNA and subsequent culture. Cells and supernatants were 
harvested at 48h. (B) DLL4 detected in culture supernatants by ELISA. (C) 
Western blot of cleaved/activated Notch1 (N1ICD). Fold induction relative to 
Mock is represented below each lane. (D-E) Pro-inflammatory cytokines TNFα 
(D), and CCL2 (E) detected in culture supernatants by ELISAs. (F) Flow 
cytometry histograms of CD11c expression in transfected BMDM. (G) 
Percentage increase in CD11c+ macrophages. For figures B-F, values are 
presented as mean ± SEM and are from a single experiment representative of 2-
3 independent experiments. For figure E, data presented are mean ± SEM of 3 
independent experiments. Statistical significance was determined by one-way 

































































































































































Figure 2.6 MicroRNA-30 Inhibitor LNAs downregulate miR-30 Expression. 
As described in Figure 2.5 BMDM were transfected with miR-30 inhibitor LNAs. 
qRT-PCR estimation of miR-30 knockdown in LNA-transfected BMDMs. miR-30-
5p inhibitor LNAs decrease expression of their designated mature miRs however 
they do display some cross-reactivity to other miR-30 family miRs. Values 
presented are mean ±SEM and are from a single experiment representative of 2 
independent experiments. Statistical significance was determined by one-way 
ANOVA with Bonferroni post hoc correction. For pairwise comparisons, p<0.05 if 
letter differs between the groups being compared. 
 
 
Figure 2.7 Inhibition of DLL4-Notch signaling lessens inflammation in miR-
30 inhibitor-transfected macrophages.  
Bone marrow derived macrophages were transfected with LNA as performed in 
Figure 2.5, and then cultured in the presence of vehicle (DMSO), the Notch/γ-
secretase inhibitor DAPT, control IgG (Ctrl IgG), or anti-DLL4 antibody (α-DLL4 
Ab, clone: HMD4-1). (A) Experimental timeline. (B) Flow cytometry percentage of 
CD11c+ M1 macrophages. (C) TNFα concentration in cellular supernatant 
measured by ELISA. (D) CCL2 concentration in cellular supernatant measured 
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Figure 2.8 Lentiviral overexpression of miR-30a-5p in RAW264.7 
macrophages reduces inflammation.  
RAW264.7 macrophages were transduced with control lentivirus (LV-miR-Blank) 
or miR-30a-5p lentivirus (LV-miR-30a-5p), then M1 macrophage phenotype was 
assessed. (A) Flow cytometry percentage of CD11c+ cells. (B) TNFα 
concentration in cellular supernatant measured by ELISA. (C) CCL2 
concentration in cellular supernatant measured by ELISA. *p<0.05 
 
Figure 2.9 DNA Methylation-Dependent Regulation of miR-30. 
As shown in Figure 2.1, F4/80+ ATMs were isolated from epididymal fat of 22-
week-old HFD-induced obese and lean mice. Gene expression and DNA 
methylation were evaluated in ATMs.  (A) Volcano plot displaying linear FC of 
genes encoding epigenetic modification enzymes and factors. Fold change and p 
value observations were extracted from transcriptome microarrays (See Figure 
2.1 and Figure 2.2). (B) IGB visualization of meDIP-seq peak intensity of DNA 
methylation in the Nfyc promoter CpG island. (C) Methylation-specific PCR 
quantification of DNA methylation (DNAme) in the Nfyc promoter CpG island. For 
(A and C), values presented are representative of 3 independent experiments 
with 20 pooled NCD mice and 10 pooled HFD mice per experiment. For (B), data 
are representative of one experiment of 60 pooled LFD and 30 pooled HFD mice. 
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Figure 2.10 Illustrative summary.  
At steady state, lean ATMs express elevated miR-30, which inhibits Delta-like-4 
(DLL4) and Notch signaling-induced inflammation. Obesity promotes 
inflammation and M1 ATM polarization. DNA hypermethylation of mir30 
downregulates miR-30 expression in obese ATMs, which leads to upregulation of 




CANNABINOID RECEPTOR 1 BLOCKADE ATTENUATES OBESITY AND  
ADIPOSE TISSUE TYPE 1 INFLAMMATION THROUGH MIR-30E-5P 
REGULATION OF DELTA-LIKE-4 IN MACROPHAGES AND CONSEQUENTLY  
DOWNREGULATION OF TH1 CELLS2 
																																								 																				
2 Miranda, K., P. Mehrpouya-Bahrami, P.S. Nagarkatti, and M. Nagarkatti. (2019) 
“Cannabinoid receptor 1 blockade attenuates obesity and adipose tissue 
type 1 inflammation through miR-30e-5p regulation of Delta-like-4 in 
macrophages and consequently downregulation of Th1 cells.” Frontiers in 
Immunology. 10:1049. 




Obesity is characterized by chronic low-grade inflammation that 
contributes to development of cardiometabolic disorders.  Cannabinoid receptor 
1 (CB1) antagonists attenuate diet-induced obesity (DIO) and related 
inflammation, although the precise anti-inflammatory mechanisms involved have 
not been fully explored. In the current study we used a mouse model of DIO 
intervention to determine the microRNA (miRNA, miR)-mediated anti-obesity and 
anti-inflammatory effects of the CB1 antagonist, AM251. DIO mice that were fed 
high-fat diet (HFD) for 12 weeks were treated with AM251 (10mg/kg) for an 
additional four weeks. HFD+AM251 mice experienced rapid and prolonged 
weight loss and reduced inflammatory M1 adipose tissue macrophage (ATM) 
infiltration. To investigate miRNA-mediated regulation of ATMs, F4/80+ cells from 
stromal vascular fractions of epididymal fat were subjected to miR microarray 
analysis. Several miRs were differentially expressed in AM251-treated mice that 
were independent of calorie restriction. Prominently, miR-30e-5p was 
upregulated in ATMs from HFD+AM251 mice while the miR-30e-5p target, DLL4, 
was downregulated. Consistent with a decrease in DLL4-Notch signaling, fat 
storage and pro-inflammatory cytokine/chemokine expression was reduced 
following AM251 treatment. Furthermore, we found that AM251-treated 
macrophages can suppress DLL4-mediated Th1 polarization in CD4+ T cells. 
Together these data demonstrate that blocking CB1 receptors leads to 
upregulation of miR-30e-5p and down regulation of DLL4 in ATMs, which in turn 
suppress DLL4-Notch signaling-induced polarization of inflammatory Th1 cells 
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and adipocyte energy storage. This combined effect of ATMs and T cells leads to 
an anti-inflammatory state and attenuation of diet-induced obesity. These data 




Obesity is a chief contributor to the global health burden as the World 
Health Organization estimates nearly forty percent of the population is 
overweight or obese. Obesity presents a risk to development of comorbid 
disorders such as type II diabetes, cardiovascular disease, and cancer (Haslam 
and James 2005; Kerr, Anderson, and Lippman 2017). Causes of obesity can be 
environmental— such as diet composition, overconsumption, and physical 
inactivity; or genetic— such as having a genetic mutation in the genes encoding 
the satiety hormone leptin or its receptor (Haslam and James 2005; MacReady 
2014). All things considered, environmental factors involving poor diets, such as 
high-fat diets, are a driving force in the ongoing expansion of the disease.  
 Therapeutic strategies employed to combat diet-induced obesity (DIO) 
include lifestyle modifications and pharmacological interventions. While lifestyle 
changes would be most effective to curtail the obesity pandemic, such changes 
can be difficult to attain and/or maintain and combinations with pharmacological 
therapy have been shown to improve health outcomes (Yanovski and Yanovski 
2014). Notably, the endocannabinoid (eCB) system is a major target for 
pharmacological therapy as its over activation is associated with obesity. The 
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eCB system is comprised of cannabinoid receptors type 1 and 2 (CB1 and CB2) 
and their endogenous ligands called “endocannabinoids”. CB1 expression is 
highly concentrated in the central nervous system and to a lesser extent in 
peripheral metabolic tissues, as well as, immune cells. Thus, CB1 is highly 
involved in appetite and metabolic regulation. Nearly two decades ago, it was 
discovered that activation of CB1 increases appetite and could promote 
development of obesity (Di Marzo et al. 2001). Thus, CB1 knockout mice were 
found to be resistant to development of DIO (C. Ravinet Trillou et al. 2004, 1). 
This led to the use of SR141716A (aka Rimonabant), a CB1 antagonist that 
reduces food intake, to treat DIO (Rinaldi-Carmona et al. 1994; Jbilo et al. 2005, 
1; Christine Ravinet Trillou et al. 2003, 1). Unfortunately, adverse 
neuropsychiatric side effects caused this drug to fail to gain US Food and Drug 
Administration approval (Sam, Salem, and Ghatei 2011). However, research into 
unveiling the mechanisms by which CB1 blockade attenuates obesity has 
continued in the hopes of identifying additional target pathways for obesity 
treatment.   
 Another opportunity for attenuating obesity is targeting inflammation. 
Obesity is well characterized as having a state of chronic low-grade inflammation 
(Haiyan Xu et al. 2003). Increased adiposity initiates a switch from anti-
inflammatory pro-insulin sensitive type 2 immune surveillance, to pro-
inflammatory type 1 metabolic inflammation, which promotes metabolic 
dysfunction (Haiyan Xu et al. 2003). In adipose tissue, excess fat storage and 
adipocyte death leads to recruitment, polarization, and proliferation of pro-
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inflammatory M1 adipose tissue macrophages (ATMs), which secrete cytokines 
such as TNFα, IL-6, CCL2, and IL-1β that decrease adipocyte insulin sensitivity 
and promote tissue damage (Amano et al. 2014; Boutens and Stienstra 2016). 
Additionally, M1 ATMs can act as antigen presenting cells to stimulate adaptive 
immune responses such as Th1 polarization and interferon gamma (IFNγ) 
production in CD4+ T cells, which further impairs insulin sensitivity (Morris et al. 
2013; Winer et al. 2009). Pro-inflammatory ATMs dominate obese adipose tissue 
and therefore therapeutic strategies that reduce or skew ATMs from M1 to anti-
inflammatory M2 phenotypes have been reported to improve tissue homeostasis 
and metabolism (Darkhal et al. 2015; Zheng et al. 2015). Interestingly, work done 
by our group has shown that treatment of DIO mice with the CB1 antagonist 
SR141716A reverses obesity and is associated with a decrease in ATM-
dependent inflammation in epididymal fat of high-fat diet (HFD)-induced obese 
mice (Mehrpouya-Bahrami et al. 2017).  
 Macrophages are heterogeneous myeloid-derived innate immune cells 
that are capable of polarizing between a broad spectrum of pro- (M1) and anti- 
(M2) inflammatory phenotypes. Dynamic switching of their polarization state and 
gene expression can be achieved through microRNA (miRNA, miR)- mediated 
regulation (Zhang et al. 2013). miRNAs are short, non-coding RNAs that repress 
mRNA translation through complementary binding of a seed sequence with the 3’ 
untranslated region (3’UTR) of target mRNAs (Bartel 2004). Recently, we 
characterized dysregulated miRNAs in ATMs during DIO, which indicated miRNA 
expression in ATMs modulates their inflammatory phenotype (Miranda et al. 
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2018).   Importantly, miRNA-based therapeutics are currently being developed 
and tested for treatment of a variety of disorders including cardiovascular and 
metabolic diseases (Chakraborty et al. 2017). Thus, identification of miRNA 
involved in DIO, may help develop miRNA-based treatment modalities.   
 Notch signaling is an evolutionarily conserved signaling pathway that is 
involved in cellular development and cell-cell communication. It regulates a 
variety of cellular processes such as proliferation, differentiation, survival, and 
inflammation (Guruharsha, Kankel, and Artavanis-Tsakonas 2012). The Notch 
ligand Delta-like 4 (DLL4) contributes to many cardiometabolic disease 
mechanisms. In macrophages, DLL4 expression can be induced by M1-
promoting stimuli such as the toll-like receptor 4 (TLR4) ligands 
lipopolysaccharide (LPS), IL-1β, and minimally modified low-density lipoprotein 
(Nakano et al. 2016). Macrophage DLL4-Notch signaling promotes a feed-
forward loop of inflammatory polarization through nuclear factor κB and interferon 
regulatory factor 8 transcriptional pathways leading to production of pro-
inflammatory cytokines such as TNFα and CCL2 (Nakano et al. 2016; Haixia Xu 
et al. 2012, 8). Additionally DLL4+ macrophages can signal through Notch1 on 
other cell types such as adipocytes and CD4+ T cells to promote excess energy 
storage and Th1 polarization, respectively (Morris et al. 2013; Bi et al. 2014; 
Skokos and Nussenzweig 2007; Amsen et al. 2004). Thus targeting the DLL4-
Notch1 signaling pathway would be highly beneficial in treatment of 
cardiometabolic disorders. DLL4 blockade has been shown to improve 
atherosclerosis and metabolic disease while Notch1 blockade promotes 
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browning of white adipose tissue and improves energy expenditure and 
metabolism (Fukuda et al. 2012; Bi et al. 2014). Interestingly, miRNAs that target 
DLL4 have also been identified and include the miR-30 family (Bridge et al. 2012, 
4; Shan et al. 2016, 4).  
In the current study, we used a mouse model of DIO intervention to 
characterize miRNAs regulated by CB1 blockade in ATMs. DIO mice were 
treated with the high affinity CB1 antagonist AM251. We found several miRNAs 
to be differentially expressed following AM251 treatment that were independent 
of food restriction. Notably, miR-30e-5p was induced following AM251 treatment 
in DIO mice and was accompanied by a decrease in pro-inflammatory gene 
expression and reduced plasma IFNγ concentration. CB1 blockade in 
macrophages also suppressed Dll4-mediated Th1 polarization in lymphocytes. 
Our findings support a role for CB1 in regulation of miRNAs that dampen ATM 
inflammation and improve metabolism, which suggests that manipulation of 
miRNA in ATMs could be used to treat DIO and other inflammatory disorders. 
 
3.3 MATERIALS AND METHODS 
Mice 
Sixteen-week-old C57Bl/6J DIO (JAX Stock # 380050 & 380056) mice 
were obtained from The Jackson Laboratory and maintained on purified diets of 
either HFD (60% kcal from fat, D12492, Research Diets) or LFD (10% kcal fat, 
D12450J, Research Diets). Mice were housed in an AAALAC-accredited, 
specific-pathogen-free facility at the University of South Carolina School of 
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Medicine. After two weeks acclimation and 12-weeks of diet feeding, mice were 
treated with 10mg/kg AM251 (1117, Tocris) or Vehicle by oral gavage daily for 4 
weeks. At the conclusion of the study, mice were euthanized by overdose 
isoflurane inhalation. All experiments were performed according to protocols 
approved by the University of South Carolina Institutional Animal Care and Use 
Committee. 
Analytical procedures 
Body composition was determined by dual-energy x-ray absorptiometry 
(DEXA) in isoflurane-anaesthetized mice. Body weight measurements were 
determined using an electronic gram scale with precision ± 0.1g. Blood glucose 
concentration was determined in 5h fasted mice by applying approximately 5uL 
tail-tip blood to a glucose test strip in a glucometer (Contour Next, Bayer). 
Fasting plasma insulin concentration was determined by ELISA kit according to 
manufacturer protocol including a standard curve (ThermoFisher Scientific). The 
homeostatic model assessment of insulin resistance (HOMA-IR) index was 
calculated by the equation (Fasting glucose x fasting insulin / 405) (Matthews et 
al. 1985). 
Adipose tissue dissociation 
Stromal vascular fractions (SVF) of epididymal fat were isolated by 
collagenase digestion as previously detailed (Miranda et al. 2018). In brief, 
minced adipose tissue was placed in Hank’s Balanced Salt Solution containing 
2% bovine serum albumin (BSA) and 1mg/mL collagenase then homogenized 
with a gentleMACs dissociator (Miltenyi Biotec), and incubated for 30-40 minutes 
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at 37°C with gentle shaking until fully dissociated. SVF cells were pelleted and 
floating adipocytes removed. SVFs were filtered, RBC-lysed, and washed, then 
used immediately for either flow cytometry or ATM isolation. To isolate ATMs, 
SVF cells were labeled with either Fluorescein isothiocyanate (FITC)- or 
Phycoerythrin (PE)-anti-F4/80 antibody (Clone: BM8, Biolegend) then F4/80+ 
ATMs were immunomagnetically selected with either FITC- or PE-Positive 
Selection Kit (StemCell Tech). Flow cytometry was used to evaluate selection 
purity, which was routinely >75%. 
Flow cytometry 
SVF cells or co-cultured cells were washed in staining buffer consisting of 
phosphate buffered saline (PBS), 2% heat-inactivated fetal bovine serum (FBS), 
and 1mM EDTA. Blocking of Fc receptors was performed by incubation with 
TruStain FcX (BioLegend) for 10m. Next, cells were incubated with appropriate 
fluorochrome-conjugated antibodies for 30m on ice (CD45-APC/Cy7, clone: 30-
F11; CD11b-AlexaFluor700, clone: M1/70; F4/80-BV421, clone BM8; T-bet-
BV605, clone 4B10, CD4-APC-Cy7, clone GK1.5). Cells were washed 3X in 
staining buffer then analyzed on a BD FACSCelesta flow cytometer. Data was 
analyzed with FlowJo v10 software. 
RNA purification, cDNA synthesis, and qRT-PCR 
ATMs were lysed in Qiazol and total RNA was purified with Qiagen 
miRNeasy Micro/Mini kit. RNA concentration and purity was measured using a 
NanoDrop 2000 spectrophotometer or Agilent Bioanalyzer. RNA was reverse 
transcribed to cDNA with the miScript II RT kit (Qiagen). Quantitative RT-PCR 
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was performed with miScript SYBR Green PCR kit (Qiagen) or SSO Advanced 
Universal SYBR Green (BioRad). MiScript miRNA Primer Assays (Qiagen) were 
used for miRNA qRT-PCR. Genes were amplified with the following primers 
purchased from Integrated DNA Technologies— Beta-Actin: Fwd-GGC TGT ATT 
CCC CTC CAT CG, Rev-CCA GTT GGT AAC AAT GCC ATG T; Tnfa: Fwd-CTG 
AAC TTC GGG GTG ATC GG, Rev-GGC TTG TCA CTC GAA TTT TGA GA; 
IL6: Fwd-CCA AGA GGT GAG TGC TTC CC, Rev-CTG TTG TTC AGA CTC 
TCT CCC T; Ccl2: Fwd-TTA AAA ACC TGG ATC GGA ACC AA, Rev-GCA TTA 
GCT TCA GAT TTA CGG GT; Ccl3: Fwd-TTC TCT GTA CCA TGA CAC TCT 
GC, Rev-CGT GGA ATC TTC CGG CTG TAG. Fold change in expression was 
determined by the comparative cycle method (2-ΔΔCt). 
MicroRNA microarrays and analysis 
ATM RNA was prepared for microRNA microarrays and microarrays 
performed as previously described (Mehrpouya-Bahrami et al., in review). Probe 
signal values were used to determine linear fold change between pairwise 
comparisons. Log2 fold change values were then calculated. MiRNAs were 
considered differentially expressed between groups if the Log2 fold change was 
at least ±2. Mean normalized expression (MNE) was calculated for each of the 
dysregulated miRs and a heatmap displaying MNE was made with GraphPad 
Prism Version 7.000 (GraphPad Software). 
Immunofluorescence and histology 
Epididymal fat pads were fixed in 4% paraformaldehyde and embedded in 
paraffin. Five µm tissue sections were cut, deparaffinized, and rehydrated then 
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incubated in blocking buffer consisting of 1X PBS and 1% (w/v) BSA for 30m. 
Tissues were then incubated with 1ug TruStain FcX (Clone: 93, BioLegend) for 
10m followed by primary antibodies (F4/80-AlexaFluor488, clone: BM8, [1:100], 
BioLegend; DLL4-unconjugated, clone: HMD4-1, [1:100] BioLegend) for 30m at 
room temperature. DLL4 signal was amplified with Biotin Goat-anti-Armenian 
Hamster IgG, (Clone: Poly4055, [1:500], BioLegend) followed by Streptavidin-
DyLight 633 [1:1000], Invitrogen 21844). Tissues were counterstained with 40uM 
Hoechst 33342 (Molecular Probes H21492), and 2ug Phalloidin-
tetramethylrhodamine (Sigma P1951), then mounted with ProLong Diamond 
Anti-fade Mountant (ThermoFisher P36965). Hematoxylin and eosin (H&E) 
staining of epididymal adipose tissue sections was performed by the University of 
South Carolina Intrumentation Resource Facility under standard protocols. 
Adipocyte size was quantified using the Adiposoft plugin in FIJI (FIJI is Just 
ImageJ, NIH) (Galarraga et al. 2012). 
Confocal imaging and analysis 
Confocal microscopy and analysis were performed as previously 
described (Miranda et al. 2018). In brief, confocal images of sectioned epididymal 
adipose tissue were taken on a Zeiss LSM 510 Meta Confocal Scanning Laser 
Microscope. Five images per sample were acquired using a 40X water 
immersion objective. Original LSM data files were imported into Fiji (Fiji Is Just 
ImageJ, NIH) then split into channels. Thresholds were applied to the Cy5 
channel using Fiji’s max Entropy algorithm to identify regions of interest (ROI) 
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that express DLL4. Then, area was measured for each ROI. Each biological 
replicate is the mean expression of 5 images. 
Macrophage: lymphocyte co-culture 
Bone marrow derived macrophages (BMDM) were generated by isolating 
bone marrow cells from the tibia and femur of 6-8 week old naïve female 
C57Bl6/J mice and culturing in complete DMEM/F12 medium supplemented with 
10% heat-inactivated FBS, 1% penicillin/streptomycin, 2mM L-glutamine, and 
1U/mL macrophage-colony stimulating factor (M-CSF, Biolegend 576406) for 7 
days as previously described (Miranda et al. 2018). Lymphocytes from 
mesenteric, inguinal, axillary, and cervical lymph nodes were isolated from naïve 
6-8 week old female C57Bl6/J mice as previously described (Becker, Nagarkatti, 
and Nagarkatti 2018). Day 7 BMDM were re-plated in complete RPMI 1640 
medium supplemented with 10% heat-inactivated FBS, 1% 
penicillin/streptomycin, 2mM L-glutamine, 10mM HEPES buffer, and 0.0002% β-
mercaptoethanol. Next the BMDM were pretreated with AM251 (10uM), α-DLL4 
blocking mAb (1ug/mL), AM251 (10uM) + α-DLL4 (1ug/mL), or appropriate 
vehicle and isotype controls for 1 hr. Then, polarization factors were added to the 
medium. For polarization to M1, 100ng/mL LPS + 50ng/mL IFNγ was added 
(eBioscience 00-4976 and BioLegend 575302).  For M2, 10ng/mL IL-4 was 
added (BioLegend 574302). The cells were cultured for 24hr then BMDM 
supernatant was collected and the BMDM were washed, counted, and co-
cultured at ratios 1:1 or 1:3 (BMDM:lymphocyte) with naïve lymphocytes. 1x105 
macrophages were cultured with either 1x105 lymphocytes (1:1) or 3x105 
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lymphocytes (1:3).  ConcanavalinA (ConA, Sigma C5275) was added to the 
culture at a dose of 1ug/mL to induce Th1 cell polarization. After 48hr of co-
culture, the cells were collected for flow cytometry and supernatants were 
isolated for IFNγ ELISA (BioLegend 430801). BMDM supernatants were used for 
TNFα ELISA to confirm M1 polarization. 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism Version 7.000 
for Mac (GraphPad Software). Values are expressed as mean ± standard error. 
One-way ANOVA was used for multiple group analyses. Two-way ANOVA was 




CB1 blockade with AM251 reverses DIO 
 To study the anti-obesity and anti-inflammatory effects of weight loss due 
to CB1 blockade, we used a well-established DIO intervention model whereby 6-
week-old mice were fed HFD or control LFD for 12 weeks to induce an obese or 
lean phenotype, respectively. Following 12 weeks of purified diet feeding, 
baseline body composition was measured by DEXA and HFD-fed mice were 
stratified into experimental groups with equivalent mean fat mass. The mice were 
then treated with the CB1 antagonist AM251 at a dose of 10mg/kg or Vehicle 
(Veh, 0.1% Tween80) for 4-weeks by daily oral gavage while continuing purified 
diet (Figure 3.1A). The experimental groups included: ad libitium fed LFD+Veh 
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(lean reference), ad libitum fed HFD+Veh, ad libitum fed HFD+AM251, and a 
Vehicle-treated HFD group that was pair-fed to the HFD+AM251 group (called 
“HFD-Pair-fed”).  
 During the study, LFD+Veh mice maintained their initial body weight and 
HFD+Veh mice gained 15% of their baseline weight (Figure 3.1B).  In contrast, 
HFD+AM251 mice experienced rapid and sustained weight loss during the 4-
week DIO intervention model (Figure 3.1B). Acute weight loss was observed 
during the first week, which coincided with intense suppression of appetite 
(Figures 3.1B and 3.1C). For the remainder of the study, AM251-treated mice 
experienced persistent weight loss of approximately 20% their starting weight 
despite an increase in appetite (Figure 3.1B).  Furthermore, appetite-independent 
weight loss was observed in HFD+AM251 mice as the HFD-Pair-fed group lost 
significantly less weight than the AM251-treated mice (Figure 3.1B). At the end of 
the study, the HFD-Pair-fed group was ~94% of it’s baseline weight. Body weight 
changes were consistent with alterations in adiposity and not lean mass (Figure 
3.1C). DEXA scans showed that fat mass was increased in HFD+Veh mice, 
decreased in HFD+AM251 mice, and unchanged in LFD+Veh and HFD-Pair-fed 
mice when compared to baseline measures (Figure 3.1C).  
 Glucose intolerance and decreased insulin sensitivity are hallmarks of the 
obese state. To evaluate AM251-dependent effects on glucose metabolism; 
fasting glucose, fasting insulin, and a homeostatic model assessment of insulin 
resistance index (HOMA-IR) were determined. HFD+AM251 mice did not 
experience an increase in fasting glucose over the duration of the 4-week 
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intervention, whereas HFD+Veh and HFD-Pair-fed experienced significant 
increases in fasting glucose (Figure 3.1D). AM251-treatment in HFD-fed mice 
also led to decreases in fasting insulin and HOMA-IR measurements that were 
similar to LFD+Veh mice (Figures 3.1E-3.1F). Although, these decreases may be 
primarily an effect of decreased appetite as HFD+AM251 measures were similar 
to those in HFD-Pair-fed mice (Figures 3.1E-3.1F). 
AM251 treatment in DIO mice reduces adipose tissue macrophage accumulation 
A chief characteristic of obesity is adipose tissue inflammation, which can 
lead to metabolic dysfunction. ATMs are the key initiators and instigators of this 
inflammation as they typically dominate obese adipose tissue through monocyte 
recruitment and local proliferation (Amano et al. 2014; Boutens and Stienstra 
2016). To determine macrophage burden in adipose tissue, stromal vascular 
fractions (SVF) of epididymal fat were isolated after the 4-week intervention and 
subjected to flow cytometry analysis (Figure 3.2A). The percentages and total 
cell numbers of CD45+CD11b+F4/80+ ATMs and CD45+CD11b+F4/80+CD11c+ 
M1 ATMs in SVFs were elevated in HFD+Veh mice vs. LFD+Veh mice, and 
reduced in HFD+AM251 mice vs. HFD+Veh and HFD-Pair-fed (Figures 3.2A, 
3.2C, 3.2E). Epididymal fat pad mass was also reduced in AM251-treated mice 
(Figure 3.2B). To account for alterations in fat mass, ATM number per gram of 
adipose tissue was calculated and likewise AM251 treatment led to a reduction in 
ATM number that was significant when compared to HFD+Veh group and 




AM251 intervention modulates miRNA expression in ATMs 
Next we determined if AM251-intervention alters miRNA expression in 
ATMs as we have previously shown that miRNA dysregulation is observed in 
ATMs from obese mice and contributes to their inflammatory state (Miranda et al. 
2018). To perform this, F4/80+ ATMs were isolated from epididymal fat and used 
for miRNA microarray analysis. Of approximately 3000 miRs tested, 41 and 25 
were found to be up- and down-regulated, respectively in HFD+AM251 vs. 
HFD+Veh. Additionally, 123 and 42 were up- and down-regulated, respectively in 
HFD+AM251 vs. HFD-Pair-fed. Also, 196 were up- and 70 were down-regulated 
in LFD+Veh vs. HFD+Veh. 
 To distinguish differentially expressed miRs in HFD+AM251 ATMs that 
were independent of appetite restriction, we identified miRs that were similarly 
dysregulated in HFD+AM251 vs. HFD+Veh and in HFD+AM251 vs. HFD-Pair-
fed. This analysis led to identification of 35 miRNAs that were differentially 
expressed due to appetite-independent AM251 treatment. Of these 35 miRNAs, 
24 were up-regulated and 11 were down-regulated (Figure 3.3A and Table 3.1). 
A core analysis of these miRs with Qiagen Ingenuity Pathway Analysis (IPA, 
Qiagen) revealed significant overlap (p<0.05) with processes such as cancer, 
inflammatory response, metabolic disease, and hepatitis (Figures 3.4A and 
3.4B). Furthermore, the top affected networks involved carbohydrate metabolism 
and cell cycle (Figures 3.4C and 3.4D). Interestingly, miR-30e-5p expression was 
found to be elevated in HFD+AM251 (Figure 3.3A), which as per the IPA analysis 
was associated with DLL4-Notch signaling-induced inflammation (Figure 3.3B). 
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In addition, miR-30 was found to target the Dll4 3’UTR which was conserved 
among humans and mice (Figure 3.3C).  
AM251 treatment leads to induction of miR-30e-5p and reduces DLL4 
 Next, we validated expression of miR-30e-5p in F4/80+ ATMs by qRT-
PCR (Figure 3.3D). Consequently, we evaluated protein expression of the miR-
30e-5p target DLL4 in adipose tissue by immunofluorescence (Figures 3.3E and 
3.3F). DLL4 expression was significantly decreased in HFD+AM251 vs. 
HFD+Veh (Figures 3.3E and 3.3F).  
CB1 blockade reduces energy storage and type 1 adipose tissue inflammation 
Dll4-Notch1 signaling has been characterized to promote energy storage and 
type 1 inflammatory responses. Consistent with a decrease in DLL4, epididymal 
adipocyte size and fat mass was reduced following AM251 treatment (Figures 
3.5A, 3.5B, 3.5B). We performed qRT-PCR of pro-inflammatory genes in ATMs, 
which revealed that Tnfa, Ccl2, IL6, and CCL3 expression are reduced following 
AM251 treatment in vivo (Figure 3.5C). In accordance with a decrease in M1 
ATM activation and DLL4 expression, the Th1 response was reduced in 
HFD+AM251 vs. HFD+Veh-treated mice as evidenced by decreased levels of 
circulating IFNγ (Figure 3.5D). 
AM251 reduces Th1 inflammation by regulating macrophage DLL4 
To test the possibility that AM251-mediated suppression of DLL4 was 
causing reduced Th1 polarization, we pre-treated naïve BMDM with anti-DLL4 
blocking antibody (α-DLL4), AM251, or AM251 + α-DLL4, then added polarization 
factors to the medium to promote M1 (LPS + IFNγ) or M2 (IL-4) phenotypes. 
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After 24hr of polarization, the BMDM supernatant was collected and used for 
TNFα ELISA to confirm M1 polarization (Figure 3.6A) Next, the BMDM were 
washed and co-cultured with naïve lymphocytes in the presence of the T-cell 
mitogen, ConA for 48hr. Culture of lymphocytes alone with ConA was able to 
induce a Th1 response as evidenced by elevated T-bet expression and IFNγ 
secretion (Figure 3.6B and 3.6C). The most Th1 polarization was observed in the 
M1-DMSO+IgG vehicle/Isotype control co-culture (Figures 3.7A-3.7C). Blocking 
DLL4 signaling (M1-DMSO+α-DLL4) caused reduced Th1 polarization (Figures 
3.7A-3.7C).  Similarly, CB1 blockade with AM251 reduced Th1 polarization to the 
same extent as blocking DLL4 alone (Figures 3.7A-3.7C). Blocking of both CB1 
and DLL4 led to little change in Th1 polarization versus blocking of CB1 alone or 
DLL4 alone (Figures 3.7A-3.7C).  As expected, lymphocyte IFNγ production was 
observed only in M1 co-cultures as M2 co-cultures served as a negative control 
(Figure 3.7B and 3.7C). 
 
3.5 DISCUSSION 
ATMs are a dominant cell type in the adipose tissue of obese individuals 
and their production of inflammatory mediators contributes to metabolic 
dysfunction and progression towards development of cardiometabolic disorders. 
Therapies that decrease ATM-dependent inflammation are thought to have great 
potential for decreasing the incidence of obesity and complications (Red Eagle 
and Chawla 2010). In the current study, we identified miRNAs in ATMs that are 
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associated with decreased inflammation and weight-loss due to pharmacological 
intervention of DIO with the CB1 antagonist AM251. 
 The CB1 receptor is well known to modulate appetite and energy 
homeostasis. Blockade of CB1 activation attenuates obesity by affecting multiple 
areas including leptin signaling, white adipose tissue browning, gut microbiota 
interactions, and reducing inflammation (Di Marzo et al. 2001; C. Ravinet Trillou 
et al. 2004; Jbilo et al. 2005; Christine Ravinet Trillou et al. 2003; Mehrpouya-
Bahrami et al. 2017; Azua et al. 2017). In this study and consistent with previous 
reports, we found that AM251 induces weight loss, improves glucose 
metabolism, and decreases adipose tissue inflammation.  
 To further understand regulation of ATM inflammation in this model, we 
investigated miRNAs by use of microarrays. MiRNAs are important regulators of 
gene expression because it is thought that approximately 60% of genes are 
conserved targets for miRNAs (Bartel 2004). Alterations in miRNA expression 
can also lead to quick changes in gene expression and use of miRNAs for 
therapeutic purposes holds high potential. We found that treatment of DIO mice 
with AM251 for 4-weeks led to various alterations of miRNA expression in ATMs 
from epididymal fat. Furthermore, use of a pair-fed control led to identification of 
several of miRs that were independent of AM251-induced appetite restriction. 
Therefore, we identified several miRNAs that may be involved in regulation of 
enhanced energy expenditure not due to calorie restriction. These miRNAs were 
also found to have overlap with several pathways relating to obesity-associated 
comorbid disorders including cancer, hematological disease, immunological 
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disease, and metabolic diseases. Together these data indicate miRNA-mediated 
regulation of ATMs contribute to attenuation of obesity by reducing adipose 
tissue inflammation, improving energy metabolism, and inducing weight-loss 
during DIO intervention with AM251. 
 Excitingly, we found that miR-30e-5p was reproducibly induced following 
AM251 treatment, which indicates an association between miR-30e-5p 
upregulation and appetite-independent weight loss. This miRNA has been 
previously characterized to target DLL4 and reduce DLL4-Notch signaling 
(Bridge et al. 2012; Shan et al. 2016). We have also previously demonstrated 
that the miR-30 family is downregulated in ATMs from obese vs. lean mice, while 
DLL4 expression is increased in ATMs from obese vs. lean mice, which indicates 
that miR-30e-5p attenuates inflammation in ATMs through regulation of the 
Notch signaling pathway (Miranda et al. 2018). Downregulation of miR-30 in 
macrophages also induced secretion of pro-inflammatory mediators TNFα and 
CCL2 (Miranda et al. 2018).  Here our results support our previous findings and 
excitingly, induction of miR-30e-5p in HFD+AM251 ATMs indicates that miR-30e-
5p may be used therapeutically to dampen ATM-mediated inflammation and 
reduce obesity. Consistent with increased miR-30e-5p expression, we found that 
DLL4 expression was reduced in adipose tissue from HFD+AM251 mice. It is 
possible that miR-30e-5p could have additional beneficial effects beyond 
targeting Dll4, however, we found several parameters to be reduced in AM251 
treated mice that are consistent with a reduction in DLL4-Notch signaling. These 
include a reduction in adipocyte size and fat pad mass, which indicates reduction 
	
67 
in energy storage and an increase in energy expenditure, a reduction in ATM 
pro-inflammatory cytokine gene expression and M1 polarization, and a reduction 
in Th1 inflammation with reduced circulating IFNγ. 
 In addition, we demonstrated that blocking of CB1 receptors specifically 
on M1 macrophages could suppress their ability to promote a Th1 response in 
CD4+ T cells. This effect appears to be dependent on CB1-mediated regulation 
of DLL4 expression in macrophages as DLL4 is known to promote Th1 
differentiation and we, in this study, showed that CB1 blockade reduces 
expression of this ligand (Skokos and Nussenzweig 2007). Thus, our data 
support a mechanism whereby CB1 blockade promotes induction of miR-30e-5p, 
which downregulates macrophage DLL4 and subsequent type 1 inflammatory 
responses including M1 macrophage and Th1 CD4+ T cell polarization, along 
with production of their inflammatory cytokines including TNFα, CCL2, and IFNγ 
(Figure 3.8). 
 Previous evidence advocates that miR-30 as well as DLL4 blockade may 
be therapeutically beneficial to reducing severity of metabolic disorders. MiRNA-
30c mitigates hypercholesterolemia and atherosclerosis in mice by altering lipid 
metabolism (Irani et al. 2016; Soh et al. 2013). Additionally, miR-30b/c promotes 
thermogenesis and adipose tissue browning (Hu et al. 2015, 30). Moreover, miR-
30 expression in ATMs is inversely correlated with obesity (Miranda et al. 2018). 
DLL4 blockade also protects against atherosclerosis (Fukuda et al. 2012). 
Blocking the DLL4 receptor Notch1 also attenuates obesity (Bi et al. 2014). 
Together, these data indicate that blocking of CB1 in ATMs may contribute to 
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improvement in obesity phenotype through miR-30e-5p regulation of DLL4. 
Therefore, future studies focusing on in vivo induction of macrophage-specific 
miR-30 in DIO and other cardiometabolic models could shed new light on the 
mechanistic potential of this miRNA family for treatment of these macrophage-





Table 3.1 Dysregulated miRNAs and their experimental fold change 
observations in F4/80+ ATMs. 
 Comparison (Log2 fold change) 





mmu-miR-30e-5p 6.386 3.450 3.880 
mmu-miR-346-5p 6.979 2.131 5.107 
mmu-miR-28a-5p 3.288 2.652 4.274 
mmu-miR-28a-3p 1.451 2.253 4.292 
mmu-miR-425-3p 4.917 2.348 2.021 
mmu-miR-671-5p 3.631 2.923 4.117 
mmu-miR-668-5p -1.409 3.236 2.456 
mmu-miR-466f-3p -1.112 2.674 22.225 
mmu-miR-466i-3p -2.023 4.668 3.614 
mmu-miR-669e-3p -1.026 2.142 2.390 
mmu-miR-1894-5p 2.554 2.220 5.140 
mmu-miR-1894-3p 4.814 4.405 4.637 
mmu-miR-1946a 7.775 4.164 2.332 
mmu-miR-3081-5p 1.690 3.287 2.353 
mmu-miR-3102-5p.2-5p 4.134 3.661 5.222 
mmu-miR-6340 -1.007 2.453 3.541 
mmu-miR-6906-5p -3.464 2.037 3.136 
mmu-miR-7011-5p 2.712 2.793 3.109 
mmu-miR-7040-5p 4.105 3.438 15.522 
mmu-miR-7045-3p 1.856 17.438 4.285 
mmu-miR-7048-5p 7.016 2.653 2.538 
mmu-miR-7238-5p 2.811 4.674 5.337 
mmu-mir-883b 1.243 3.196 3.699 
mmu-mir-6414 -1.073 2.080 2.122 
mmu-miR-99b-3p 1.082 -2.413 -3.258 
mmu-miR-195a-3p 2.502 -4.601 -2.357 
mmu-miR-34c-5p 5.540 -5.626 -23.750 
mmu-miR-25-3p -1.300 -2.325 -2.021 
mmu-miR-676-3p 1.003 -2.051 -3.930 
mmu-miR-5112 1.064 -2.500 -3.202 
mmu-miR-5121 -1.968 -16.757 -4.637 
mmu-miR-6937-5p 3.597 -2.075 -2.827 
mmu-miR-6949-5p -3.261 -4.095 -2.201 
mmu-mir-466f-4 1.979 -2.734 -2.182 
mmu-mir-5112 -1.837 -4.554 -2.165 
Upregulated    




Figure 3.1 Treatment of mice with the CB1 antagonist (AM251) reverses 
obesity. 
12-week HFD-fed obese mice were treated with the CB1 antagonist AM251 
(10mg/kg) for 4 weeks to assess intervention of obesity parameters.   (A) 
Experimental timeline. (B) Percentage body weight growth and energy intake 
during the 4-week intervention.(C) DEXA body composition Pre- and Post- 4 
weeks of treatment. (D) 5hr fasting blood glucose Pre- and Post- 4 weeks of 
treatment. (E) 5hr fasting insulin after 4 weeks of treatment. (F) Insulin resistance 
index (HOMA-IR) after 4 weeks of treatment. Data are mean +/- SEM. N=5 
mice/group. Significance vs. HFD+AM251 was determined by one-way ANOVA 
(B, E&F). Significance between time points was determined two-way ANOVA 





Figure 3.2 CB1 blockade reduces abundance of pro-inflammatory 
macrophages in epididymal fat.   
HFD-fed obese mice were treated with the CB1 antagonist AM251 (10mg/kg) as 
described in Figure 3.1 legend.  Epididymal fat SVFs from AM251-treated DIO 
mice were analyzed by flow cytometry. CD45+CD11b+F4/80+ cells are 
considered as “ATMs”.   CD45+CD11b+F4/80+CD11c+ cells are depicted as “M1 
ATMs”. (A) Contour plots of ATMs. (B) Epididymal fat mass. (C) Total epididymal 
fat ATMs per mouse.(D) ATMs per gram of fat. (E) Total epididymal fat M1 ATMs 
per mouse.  (F) M1 ATMs per gram of fat. Data are mean +/- SEM. N=5 
mice/group. Significance was determined by one-way ANOVA. ****P<0.0001, 




Figure 3.3 AM251 treatment elevates ATM miR-30e-5p and reduces target 
expression of the pro-inflammatory Notch ligand Delta-like-4. 
DIO mice were treated with the CB1 antagonist AM251 (10mg/kg) as described 
in Figure 3.1 legend. MicroRNA microarrays were performed on F4/80+ ATMs 
isolated from epididymal fat after the 4-week AM251 intervention.(A) Heatmap of 
differentially expressed miRs in ATMs resulting from AM251 treatment, 
independent of effects of caloric restriction. (Log2 fold change ≥±2) (B) Qiagen 
IPA network of miRs targeting the DLL4-Notch signaling pathway and 
downstream inflammatory cytokines. Expression values and predictions are 
overlaid on the network. (C) Sequence conservation of human and mouse miR-
30e-5p binding to Dll4 3’UTR. (D) qRT-PCR of miR-30e-5p in ATMs. (E) 
Confocal microscopy quantitation of DLL4 expression in epididymal adipose 
tissue. (F) Representative confocal micrographs. Images are to equal scale. For 
A and D, data are presented from independent experiments of 4-10 pooled mice 
per group. For E, N=3 mice/group. Significance was determined by one-way 





Figure 3.4 Pathway analysis of dysregulated miRNAs following AM251 
treatment. 
Qiagen IPA was used for core analysis of dysregulated miRNAs in ATMs. (A-B) 
Top Diseases, biological functions, and toxicological functions affected by the 
dysregulated miRs. (C-D) The top 2 affected networks. Network pathways are 
depicted with overlaid expression values and predictions. Red: upregulated, 






Figure 3.5 AM251 treatment in vivo reduces energy storage and type 1 
inflammation associated with DLL4-Notch signaling. 
HFD-fed obese mice were treated with AM251 (10mg/kg) for 4 weeks as 
described in Figure 3.1 legend. Adipocyte size, ATM gene expression, and 
plasma IFNγ were quantified in mice after the 4-week AM251 intervention. (A) 
Representative H&E stains of epididymal fat. Images are to equal scale (4X). (B) 
FIJI adipocyte size quantification. (C) qRT-PCR expression of inflammatory 
cytokine/chemokine genes in F4/80+ ATMs. (D) Plasma IFNγ concentration 
measured by ELISA. Data are mean +/- SEM. For A and B, N=4-5 mice/group. 
For C, data are presented from a single experiment of 4-10 pooled mice per 
group. For D, N=3 independent experiments of pooled plasma from 4-10 
mice/group. Significance was determined by one-way ANOVA. **P<0.01, 





Figure 3.6 Confirmation of M1 polarization in BMDM and Th1 polarization in 
CD4+ T cells.  
For (A), BMDM from naïve mice were pretreated with AM251 (10uM) +/- α-DLL4 
blocking mAb (1ug/mL) or vehicle/isotype controls for 1h then polarized to M1 
(LPS+IFNγ) or M2 (IL-4) for 24 hr. Supernatants were collected for TNFα ELISA 
to confirm M1 polarization. For (B-C), naïve lymphocytes were cultured in 
medium containing 1ug/mL ConA for 48 hr. (A) TNFα concentration detected in 
BMDM supernatant by ELISA. (B) Flow cytometry of CD4+T-bet+ Th1 
lymphocytes. (C) IFNγ concentration detected in lymphocyte supernatant by 
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Figure 3.7 AM251 reduces expansion of pro-inflammatory Th1 cells by 
downregulating DLL4 in macrophages.  
BMDM were pre-treated and polarized as described in Figure 3.6 legend. After 
24hr of culture, the BMDM were washed and co-cultured with naïve lymphocytes 
at ratios of 1:1 or 1:3 (BMDM:lymphocytes) in the presence of 1ug/mL ConA for 
48 hr. Resulting Th1 polarization of  CD4+ lymphocytes was assessed. (A) Flow 
cytometry of CD4+T-bet+ Th1 lymphocytes. (B-C) IFNγ concentration in cell 





Figure 3.8 Blocking CB1 receptors reverses obesity through miR-30e-5p 
regulation of DLL4.  
In this illustrative summary we demonstrate that blocking of CB1 receptors can 
reverse the inflammation and metabolic dysfunction observed in obese adipose 
tissue. During obesity, endocannabinoids activate CB1 to promote pro-
inflammatory M1 macrophages and upregulation of DLL4. Subsequently, DLL4 
activates Notch signaling on other macrophages, T cells, and adipocytes to 
promote M1 polarization, Th1 polarization, and adipocyte hypertrophy, 
respectively. As a result, pro-inflammatory cytokines and chemokines such as 
TNFα, CCL2, and IFNγ, and fat mass expansion, lead to metabolic dysfunction. 
Conversely, blocking of CB1 with AM251 reverses DLL4-Notch signaling-
mediated inflammation and metabolic impairments due to upregulation of miR-
30e-5p and downregulation of DLL4. As a result, fewer M1 macrophages and 
Th1 cells reside in the adipose tissue and energy expenditure increases to 
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The endocannabinoid system (ECS) regulates a variety of obesity-related 
physiological processes including appetite, inflammation, and metabolism. 
Recent literature also suggests that the gut microbiota are tightly linked to obesity 
development; however, the role of the ECS in regulating obesity-induced 
intestinal dysbiosis is unclear. In the current study, genetic ablation of 
cannabinoid receptors CB1 and CB2, as well as pharmacological intervention 
were used in a mouse model of diet-induced obesity to determine the roles of the 
ECS in modulating inflammation, metabolism, and the gut microbiome. CB1-/- 
mice were resistant to high fat diet (HFD)-induced weight gain, metabolic 
dysfunction, and visceral adipose tissue M1 macrophage accumulation. 
Contrarily, CB2-/- mice displayed more severe obesity than wild-type mice.  
Additionally, treatment of obese mice with the CB1 antagonist AM251 led to 
weight loss, decreased adipose inflammation, and improvement in metabolic 
parameters. Interestingly, CB1 and CB2 were found to oppositely regulate HFD-
induced leukocyte infiltration in the cecal-colonic lamina propria. Decreased 
intestinal inflammation upon CB1-blockade indicated ECS-mediated alterations in 
the gut microbiome might contribute to obesity phenotype. Microbiota profiling by 
16S rRNA gene sequencing showed that CB1-/-, but not CB2-/- mice were 
resistant to development of HFD-induced gut dysbiosis. Moreover, AM251 
intervention in obese mice shifted their microbiota towards a lean profile. Co-
housing and fecal transfer experiments in wild-type and CB1-/- mice indicated that 
microbiota composition was largely dispensable for improved obesity in CB1-/- 
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mice, yet some composition differences remained. Further investigation of 
host:microbiota interactions by intestinal epithelial cell transcriptomics, serum 
metabolomics, and microbiota PICRUSt analyses revealed CB1-mediated 
regulation of intestinal barrier defense and gut microbiota-mediated sugar 
metabolism were involved in the pathogenesis of obesity. Together this study 
demonstrates that endocannabinoid signaling through CB1 and CB2 regulates 
metabolism by shaping intestinal immunity and mediating susceptibility to the 
obesity-associated microbial dysbiosis that promotes increased energy harvest. 
 
4.2 INTRODUCTION 
Obesity incidence is experiencing perpetual growth and robustly 
contributes to the global health burden due to many related complications that 
are triggered by chronic low-grade inflammation and metabolic dysfunction 
(Haslam and James, 2005). The endocannabinoid system (ECS) is a biological 
system that regulates a variety of obesity-related physiological processes 
including appetite, inflammation, and metabolism (Cani et al., 2016).  Thus, 
regulation of this system is of high therapeutic interest for reducing obesity. 
The ECS is comprised of cannabinoid receptors (CB) and their ligands 
called cannabinoids; named as such due to binding affinity for herbal ligands 
derived from Cannabis sativa. CBs are a class of G-protein coupled receptors 
widely expressed throughout the body. The two main cannabinoid receptors, 
CB1 and CB2, are expressed in various anatomical locations that coincide with 
their regulatory functions. CB1 expression is highly localized to the central 
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nervous system where it is well know to mediate the psychotropic effects of 
Cannabis, and additionally expressed in peripheral metabolic tissues such as the 
liver, adipose tissue (AT), muscle, gastrointestinal (GI) tract, and in some 
immune cells (Laprairie et al., 2012). As such, CB1 is heavily involved in 
regulation of energy metabolism and appetite. Conversely, CB2 is largely 
expressed in the immune system where it modulates inflammatory pathways 
including pain and cytokine release (Turcotte et al., 2016). Various studies from 
our laboratory have shown anti-inflammatory/immunosuppressive properties of 
CB2 agonists (Lombard et al., 2007; Singh et al., 2012; Tomar et al., 2015). 
Importantly, obesity is characterized by energy imbalance, chronic low-grade 
inflammation, and chronic ECS activation. Therefore, the ECS provides a 
mechanistic link between inflammation and metabolism during obesity that 
necessitates further investigation. 
 In the early 2000’s it was discovered that stimulation of CB1 promotes 
development of obesity (Cota et al., 2003; Di Marzo et al., 2001). Blockade of 
CB1 reduced food intake in rodents and thus treatment of diet-induced obese 
mice with the CB1 antagonist SR141716A led to amelioration of both obesity and 
metabolic impairments (Cota et al., 2003; Ravinet Trillou et al., 2003). 
Furthermore, CB1 knockout mice were shown to be resistant to development of 
high fat diet (HFD)-induced obesity and insulin resistance (Ravinet Trillou et al., 
2004). Indeed, pharmacological blockade or genetic ablation of CB1 lessened 
appetitive behaviors, however additional appetite-independent metabolic benefits 
were observed indicating an increase in energy expenditure when CB1 signaling 
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is impaired.  Thus, CB1 became an attractive target for treatment of the ongoing 
obesity epidemic. Unfortunately, due to adverse neuropsychiatric effects, 
SR141716A, also known as Rimonabant, was removed from market. Despite 
this, research in the last decade has further characterized mechanisms of CB1 
blockade-mediated metabolic improvements. Beneficial mechanisms of systemic 
CB1 antagonism beyond appetite regulation include decreasing obesity-
associated inflammation through microRNA regulation of adipose tissue 
macrophages (ATM), increased brown adipose tissue thermogenesis, and 
increased insulin-dependent glucose utilization (Bajzer et al., 2011; Mehrpouya-
Bahrami et al., 2019; Miranda et al., 2019). Adipocyte-specific CB1 knockout also 
increases energy expenditure and promotes anti-inflammatory M2 ATM 
polarization, which highlights the importance of peripheral CB1 receptors in 
metabolic regulation (Azua et al., 2017). In addition, recent evidence shows that 
peripherally restricted CB1 antagonists can be used to treat obesity without 
central side effects, albeit, their anti-obesity effects are slightly less than that of 
central-acting CB1 antagonists (Dong et al., 2018; Han et al., 2018).  
 While regulation of multiple obesity parameters appears to be CB1-
dependent, the role of CB2 should not be discounted due to its involvement in 
immune system regulation. Knowing that obesity promotes a stage of chronic 
low-grade systemic and metabolic inflammation, which positively correlates with 
adiposity and insulin resistance, it is likely that CB2 plays important roles in 
obesity-related processes. Recent studies have identified non-synonymous 
polymorphisms in the Cnr2 gene (the gene encoding CB2) can contribute to 
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overeating disorders (Ishiguro et al., 2010; de Luis et al., 2018). Aged CB2-/- mice 
also spontaneously develop pro-inflammatory obesity (Schmitz et al., 2016). 
Furthermore, treatment of mice with CB2 antagonists increases food intake, 
while CB2 agonists decrease appetite (Schmitz et al., 2016; Verty et al., 2015). 
Treatment of DIO mice with the CB2 agonist JWH-015 induces weight loss, 
lipolysis, and reduces inflammation in white adipose tissue (WAT), and 
additionally these effects were found to be independent of food restriction (Verty 
et al., 2015). These recent findings demonstrate that CB2 also plays key roles in 
energy homeostasis through modulation of the immune cells that contribute to 
insulin resistance, and moreover, reveals complementary roles of the CB1/CB2 
balance in regulating immunometabolism that warrant further investigation. 
Another entity that influences obesity phenotype is the community of 
trillions of microbes within the GI tract, also known as the gut microbiota (Cani, 
2014; Zhao, 2013). It is becoming increasingly evident that environmental factors 
such as diet, exercise, stress, pharmaceuticals, and the like can alter the gut 
microbiota and impact host health (Dopkins et al., 2018). During obesity, altered 
microbiota composition leads to microbial dysbiosis that impairs health by 
contributing to gut inflammation, intestinal permeability, and increased energy 
harvest (Turnbaugh et al., 2006). To date, studies on ECS regulation of DIO-
induced microbial dysbiosis are limited. Indeed a recent study from our laboratory 
demonstrated that blockade of CB1 signaling attenuates obesity and is 
associated with a shift in the gut microbiome composition that is associated with 
decreased intestinal permeability, increased microbial short chain fatty acid 
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(SCFA) production, and dampened adipose tissue macrophage (ATM)-mediated 
inflammation (Mehrpouya-Bahrami et al., 2017). Others have also demonstrated 
relationships between CB1 activation, intestinal permeability, decreased gut 
motility, and lipopolysaccharide (LPS)-regulated adipogenesis (Alhamoruni et al., 
2010; Izzo et al., 2001; Muccioli et al., 2010). These findings indicate that gut 
microorganisms and the ECS are closely connected; however, the metabolites, 
receptors and signaling pathways that couple these, need to be more clearly 
defined in order to develop new therapeutic modalities (Cani et al., 2016).  
In the current study, we used a mouse model of HFD-induced obesity in 
mice lacking functional CB1 or CB2 receptors to characterize influences of ECS 
on the gut microbiome, intestinal barrier function, inflammation, and metabolism. 
Microbiota composition and immune: microbial interactions in these models have 
not been previously reported.  We also used a DIO intervention model to confirm 
therapeutic anti-obesity mechanisms of CB1 blockade. We hypothesized that the 
ECS contributes to metabolic and inflammatory tone through modulations of gut 
microbiota composition/metabolism and/or host microbial defense mechanisms, 
primarily through CB1-dependent mechanisms. Metabolic analyses, immune 
profiling, gut bacterial predictive metagenomics, intestinal epithelial cell 
transcriptomics, and serum metabolomics revealed CB1-dependent regulation of 
intestinal integrity and barrier protection, as well as regulation of microbial 
metabolic processes that correlate with body weight gain. Loss of CB2 signaling 
also worsened some obesity-related parameters that warrant further 
investigation. This study provides new insights into beneficial mechanisms of 
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CB1 blockade that promote metabolic health through host: microbial interactions, 
which may form the basis for new therapeutic modalities for obesity and related 
disorders. 
 
4.3 MATERIALS AND METHODS 
Mice 
Six- to 8-week-old male C57Bl/6J mice and 18-week-old male C57Bl/6J 
mice fed either 60% kcal HFD (D12492, Research Diets), or purified 10% low-fat 
diet (LFD, D12450J, Research Diets) where indicated, for 12 weeks were 
obtained from The Jackson Laboratory and housed in a specific-pathogen-free 
facility. CB1-/- constitutive knockout mice were gifted from Dr. James Pickel (NIH 
National Institute of Mental Health Transgenic Core Facility, Bethesda, MD, 
USA). CB2-/- constitutive knockout mice were obtained from The Jackson 
Laboratory. CB1-/- and CB2-/- mice were bred in-house and colonies maintained 
at the University of South Carolina School of Medicine animal facility. Mice were 
housed in separate cages (3-5 mice per cage) according to treatment group in all 
experiments except for the specified co-housing experiment. In all experiments, 
each treatment group consisted of mice from multiple litters and cages. In some 
instances mice were singly housed due to fighting. For DIO intervention studies, 
12 week fed HFD-induced obese mice were stratified into treatment groups by 
equivalent mean DEXA fat mass. The treatment group was treated with AM251 
(Tocris, 1117) at a dose of 10mg/kg suspended in 0.1% Tween 80 by oral 
gavage. All other experimental groups received Vehicle (Veh) gavages. Pair 
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feeding was performed by measuring the weight of HFD consumed each day, 
then administering that same weight of food to the Pair-fed group. At the 
conclusion of each study, mice were euthanized by overdose isoflurane 
inhalation. Experiments were performed in accordance with ethical standards 
approved by the University of South Carolina Institutional Animal Care and Use 
Committee.  
Analytical Procedures 
Body composition was measured by dual-energy x-ray absorptiometry 
(DEXA, LUNAR PIXImus) scanning as previously described(Miranda et al., 
2018). Body weight was monitored using an electronic gram scale with precision 
± 0.1g. For glucose tolerance tests, mice were fasted for 5hr, then fasting 
glucose was measured followed by oral gavage of 2g/kg lean mass glucose 
(Sigma G7528). Blood glucose was measured 15m, 30m, 60m and 120m after 
glucose gavage by applying approximately 5uL tail-tip blood to a glucose test 
strip in a glucometer (Contour Next, Bayer). To calculate a homeostatic model 
assessment of insulin resistance index (HOMA-IR), mice were fasted for 5hr then 
blood glucose was measured from the tail-tip. Immediately following, mice were 
euthanized by overdose isoflurane inhalation and ~500uL portal vein blood was 
collected and gently mixed with 15uL 0.5M EDTA. To isolate plasma, blood was 
centrifuged 5000 RPM, 5 min, 4°C and the top layer was collected and stored at -
20°C. Insulin concentrations were measured in fasted plasma by ELISA 
(Invitrogen, EMINS). HOMA-IR index was calculated by the following equation 
[HOMA-IR= (fasting glucose x fasting insulin)/22.5] (Matthews et al., 1985).  
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Adipose Tissue Dissocation 
Epididymal fat pads were excised, weighted, and dissociated using MACS 
adipose tissue dissociation kit and a gentleMACS dissociator according to 
manufacturer protocol (130-105-808, Miltenyi Biotec). The isolated stromal 
vascular fraction (SVF) was spun through a 33% (v/v) isotonic Percoll solution 
(1500 RPM, 15min, 25°C) prior to flow cytometry staining. 
Intestinal dissociation for IEC and LPMC isolation 
The cecum and colon were isolated from euthanized mice, cleaned of 
fecal matter, opened longitudinally, and mucus layer removed by gentle scraping 
in 1X HBSS. Cleaned tissues were cut into 0.5 cm segments and incubated in 
pre-warmed 1X HBSS (without Ca2+ and Mg2+) containing 3% FBS, 10mM EDTA, 
and 5mM Dithiothreitol (DTT, Sigma) for 45 minutes at 37°C with shaking. The 
supernatant containing intra-epithelial leukocytes (IELs) and epithelial cells was 
recovered by filtering colon pieces through a 100um nylon mesh. This fraction 
was put on ice for at least 10 minutes to allow sedimentation of cellular debris. 
EpCAM+ IECs in the supernatant were then labeled with PE-labeled EpCAM 
(Clone G8.8, BioLegend) and immunomagnetically selected by PE-Positive 
Selection Kit (StemCell Tech). Flow cytometry was used to verify selection purity, 
which was greater than 85%. 
For LPMC isolation, the remaining colon tissue was incubated in 15 mL 
digestion buffer for 45 m at 37°C with shaking to dissociate lamina propria cells. 
Digestion buffer consisted of 1X HBSS (with Ca2+ and Mg2+) containing 3% FBS, 
1% L-glutamine, 1% penicillin–streptomycin, 10 mM HEPES, 0.5 mg/mL 
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Collagenase D (Roche), 0.5 mg/mL Dispase (Sigma), and 0.04 mg/mL DNase I 
(Sigma). The supernatant was filtered through a 70um nylon mesh into ice cold 
1X HBSS. Lamina propria cells were passed through a 40%/80% (v/v) Percoll 
(GE Healthcare) gradient and spun at 620xg for 20 minutes with low acceleration 
and no brake. LPMC at the 40/80 interface were collected and washed twice with 
Fluorescence Activated Cell Sorter (FACS) buffer (1X PBS, 2% FBS, 1mM 
EDTA) and used flow cytometry analysis.   
Isolation of spleen single cell suspensions 
Spleens were excised from euthanized mice and disrupted in 5mL FACS 
buffer utilizing a Stomacher80 machine (Seward). Homogenates were filtered 
through a 70um nylon mesh, pelleted, RBC-lysed, and washed in FACS buffer 
prior to flow cytometry staining. 
Flow Cytometry 
For surface staining, cells were incubated with FcR-Blocker for 10m 
followed by appropriate fluorochrome-conjugated antibodies for 30m (CD45 
clone 30-F11, CD11b clone M1/70, F4/80 clone BM8, CD11c clone N418, CD4 
clone GK1.5, Foxp3 clone MF-14, T-bet clone 4B10, LAP clone TW7-16B4, 
BioLegend). For intracellular staining of transcription factors, Biolegend 
TrueNuclear Intracellular Staining kit was used according to manufacturer 
protocol. Stained cells were washed with FACS buffer then analyzed on a BD 
FACSCelesta flow cytometer. Data were analyzed and visualized with FlowJo 
v10.  
Short chain fatty acid extraction and quantification 
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SCFA were acidified and extracted from flash frozen cecal contents 
according to a previously published protocol from our laboratory (Mehrpouya-
Bahrami et al., 2017). The extraction method was modified to use tert-Butyl 
methyl ether as the extraction solvent. 2-ethylbutyric acid was used as the 
internal standard. External calibration standards were prepared to determine 
retention times. Samples and standards were detected by gas chromatography 
coupled with flame-ionization detection at the University of South Carolina Mass 
Spectrometry Center. Sample concentrations were calculated as previously 
described (Mehrpouya-Bahrami et al., 2017). 
Intestinal permeability measurements 
In vivo assay of intestinal epithelial barrier permeability was performed by 
FITC-Dextran assay as previously described (Chassaing et al., 2015). Mice were 
food and water fasted for 4 h then gavaged with 15 mg of FITC-labeled 4kD 
dextran (Sigma, FD4), then re-allowed ad libitum access to food and water. 
Blood was collected retro-orbitally 4 h after gavage in isoflurane-anaesthetized 
mice. Serum was collected and diluted 1:1 (v/v) with PBS and the fluorescein 
(excitation 485nm) measurements were performed on a plate reader (Victor2). 
FITC concentration was calculated using a standard curve of serially diluted 
FITC-dextran in normal mouse serum. Lipopolysaccharide leakage into blood 
circulation was quantified in mouse serum by LPS ELISA kit (LSBio, LS-F17912). 
16S Predictive Metagenomics Sequencing and Analysis 
Stool DNA was isolated with QIAamp DNA Stool Mini Kit (Qiagen). 16S 
rRNA gene V3-V4 regions were amplified and sequencing libraries were 
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generated following the Illumina Demonstrated Protocol “16S Metagenomic 
Sequencing Library Preparation”  (Part # 15044223 Rev. B). Equimolar pooled 
libraries were quantified using Qubit dsDNA HS assay (Life Technologies) then 
sequenced using an Illumina MiSeq sequencer (paired-end reads, 2 x 301 base 
pairs). De-multiplexed FASTQ files were obtained from Illumina BaseSpace 
Sequence Hub and analyzed through the NIH Nephele pipeline (FASTQ Paired-
end 16S using QIIME)(Weber et al., 2018). Sequences were pre-processing 
filtered by a minimum quality score of 19 and max ambiguous score of 0. Reads 
were joined with a maximum bad run length of 3, minimum overlap length of 10, 
and percent differences within overlap of 25. The Greengenes_99 Reference 
database was used for a closed reference clustering and classification analysis 
including Phylogenetic Investigation of Communities by Reconstruction of 
Unobserved States (PICRUSt) annotations (Langille et al., 2013). Chimeras were 
removed using UCHIME (Edgar et al., 2011). For diversity analysis, the fraction 
of maximum sample size was set to 0.2. For Linear discriminant analysis (LDA) 
effect size (LEfSe), the Huttenhower Lab Galaxy instance 
(https://huttenhower.sph.harvard.edu/galaxy) was used(Segata et al., 2011). 
Data input were % of total operational taxonomic units (OTUs) per sequencing 
sample. All default analysis parameters were used. LEfSe results were plotted as 
cladograms in Galaxy. 
Antibiotic administration and fecal microbiota transfer 
Five-week-old male C57BL6 mice were depleted of resident microbiota by 
housing mice in autoclaved cages containing autoclaved food and sterile drinking 
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water containing antibiotics (Abx) as previously described(Li et al., 2017). The 
antibiotics administered include 1 mg/mL bacitracin, 170 ug/mL gentamycin, 125 
ug/mL ciprofloxacin, 100 ug/mL neomycin, 100 U/mL penicillin, 100 ug/mL 
metronidazole, 100 ug/mL ceftazidime, 50 ug/mL streptomycin, and 50 ug/mL 
vancomycin (Sigma) and were provided fresh once per week. After 4 weeks of 
Abx administration, stool was isolated for bacterial culture and qRT-PCR for 
Eubacteria normalized to 18S to confirm microbiota depletion. The Abx-treated 
mice were then transferred into dirty donor cages for 4 days then gavaged with 
200mg donor feces suspended in PBS, which was harvested under anaerobic 
conditions. The mice were then maintained in autoclaved cages and fed ad 
libitum irradiated HFD (Research Diets, D12492i) for 3 weeks to monitor weight 
gain. 
RNA isolation, cDNA synthesis, and qRT-PCR 
Total RNA was isolated from cells by lysing in Qiazol then using 
miRNeasy Mini/Micro kits (Qiagen) according to manufacturer protocol. When 
required, the RNA was reverse transcribed to cDNA with iScript cDNA synthesis 
kit (BioRad). Quantitative RT-PCR for mRNA expression was performed with 
SSO Advanced Universal SYBR Green supermix (BioRad). For bacterial qRT-
PCR QuantiFast SYBR Supermix (Qiagen) was used. The primers used were 
purchased from Integrated DNA Technologies (Lyz2- Fwd: ATG GAA TGG CTG 
GCT ACT ATG G, Rev: ACC AGT ATC GGC TAT TGA TCT GA, Beta-actin- 
Fwd: GGC TGT ATT CCC CTC CAT CG, Rev: CCA GTT GGT AAC AAT GCC 
ATG T , 18S- Fwd: GCC CGA GCC GCC TGG ATA, Rev: CCG GCG GGT CAT 
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GGG AAT AAC , Eubacteria- Fwd: ACT CCT ACG GGA GGC AGC AGT, Rev: 
ATT ACC GCG GCT GCT GGC).  
 
Transcriptome microarrays 
Ten ng of total RNA isolated from ccIECs was used as starting material for 
each transcriptome microarray. cDNA synthesis, in vitro transcription, cRNA 
amplification, ss-cDNA synthesis, purification and quantification steps, 
fragmentation and labeling, and hybridization to MTA1.0 chips was performed 
with the Applied Biosystems GeneChip WT Pico Reagent Kit. The hybridized 
chips were then washed, stained, and scanned on an Affymetrix GCS 3000 
system using the fluidics protocol FS450_0001. The generated .CEL files were 
analyzed for quality and normalized to converted .CHP files using Transcriptome 
Analysis Console v.4.0.1.36 (Applied Biosystems). The summarization and 
normalization method used was Gene + Exon – SST-RMA. Genes were 
considered differentially expressed between groups if the Log2 fold change was ≥ 
1.5 or ≤ -1.5. 
Serum Metabolomics 
Serum metabolomics experiments were performed at the Baylor College 
of Medicine according to previously published methods (Amara et al., 2019; 
Putluri et al., 2011a, 2011b; Vantaku et al., 2017, 2019). Reagents and internal 
standards, high-performance liquid chromatography (HPLC)-grade acetonitrile, 
methanol, and water were procured from Burdick & Jackson (Morristown, NJ). 
Mass spectrometry-grade formic acid was purchased from Sigma-Aldrich (St 
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Louis, MO). Calibration solution containing multiple calibrants in a solution of 
acetonitrile, trifluroacetic acid, and water was purchased from Agilent 
Technologies (Santa Clara, CA). Metabolites and internal standards, including N-
acetyl Aspartic acid-d3, Tryptophan-15N2, Sarcosine-d3, Glutamic acid-d5, 
Thymine-d4, Gibberellic acid, L-Threonic acid, Trans-Zeatine, Jasmonic acid, 
15N Anthranilic acid, and Testosterone-d3, were purchased from Sigma-Aldrich 
(St. Louis, MO).  
Internal Standard Solution and Quality controls- Aliquots (200 µL) of 10 
mM solutions of N-acetyl Aspartic acid-d3, Tryptophan-15N2, Sarcosine-d3, 
Glutamic acid-d5, Thymine-d4, Gibberellic acid, L-Threonic acid ,Trans-Zeatine, 
Jasmonic acid, 15N Anthranilic acid, and Testosterone-d3 were mixed and 
diluted up to 8 ml (final concentration 0.25 mM) and aliquoted into a 20 µL 
portions. The aliquots were dried and stored at -80°C. Two kinds of controls were 
used to monitor the sample preparation and mass spectrometry. To monitor 
instrument performance, 20 µL of a matrix-free mixture of the internal standards 
described above, reconstituted in 100 µL of methanol: water (50:50) and 
analyzed by SRM. Other control is use of serum pool spiked with mixture of 
internal standards, extracted along with test samples and measured by SRM. 
Sample Preparation- 50ul of each serum sample was taken. To this 750 µL ice-
cold methanol:water (4:1) containing 20 µL spiked internal standards was added 
to each tissue sample. Ice-cold chloroform and water was added in a 3:1 ratio for 
a final proportion of 4:3:2 methanol:chloroform:water. The organic (methanol and 
chloroform) and aqueous layers were mixed, dried and resuspended with 50:50 
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methanol: water. The extract was deproteinized using a 3kDa molecular filter 
(Amicon ultracel-3K Membrane; Millipore Corporation, Billerica, MA) and the 
filtrate was dried under vacuum (Genevac EZ-2plus; Gardiner, Stone Ridge, NY). 
Prior to mass spectrometry, the dried extracts were re-suspended in identical 
volumes of injection solvent composed of 1:1 water: methanol (100ul) and were 
subjected to liquid chromatography-mass spectrometry using a 6495-triple 
quadrupole mass spectrometer (Agilent Technologies, Santa Clara, CA) coupled 
to a HPLC system (Agilent Technologies, Santa Clara, CA) 
Method A: Measurement of glycolytic intermediates, TCA cycle; To target 
the glycolysis, TCA, the samples were delivered to the mass spectrometer via 
normal phase chromatography using a Luna 3 um NH2 100 A (150 x 2mm) 
(Phenomenex, Torrance, CA) in ESI/MS negative ion mode. Source parameters 
were as follows: Gas temperature was 250 °C; Gas flow was 11 l/min; Nebulizer 
was 20psi; Sheath gas temperature was 300 °C; Sheath gas flow was 11 l/min; 
Capillary was 3000 V positive and 3500 V negative; Nozzle voltage was 1500 V 
positive and 1500 V negative. The mobile phase was water solvent A modified by 
the addition of 5mM ammonium acetate (pH 9.9), and 100% acetonitrile (ACN) 
solvent B. The binary pump flow rate was 0.2 ml/min with a gradient spanning 
80% B to 2% A over a 20-minute period followed by 2% solvent B to 80% solvent 
A for a 5 min period and followed by 80% B for 13-minute. The flow rate was 
gradually increased during the separation from 0.2 mL/min (0–20 mins), 0.3 
mL/min (20.1–25 min), 0.35 mL/min (25–30 min), 0.4 mL/min (30–37.99 min) and 
finally set at 0.2 mL/min (5 min). The injection volume was 10ul. 
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Method B: In ESI positive mode the HPLC column was waters X-bridge 
amide 3.5 µm, 4.6 x 100 mm (Waters Milford, MA). Mobile phase A and B were 
0.1% formic acid in water and acetonitrile respectively. Gradient flow: 0-3 min 85 
% B; 3-12 min 30 % B, 12-15 min 2 % B, 16 min 95% B, followed by re-
equilibration till the end of the gradient 23 min to the initial starting condition of 
85% B. Flow rate of the solvents used for the analysis is 0.3 ml/min. The injection 
volume was 5µL. 
Method C:  In ESI negative mode the HPLC column was waters X-bridge 
amide 3.5 µm, 4.6 x 100 mm (Waters, Milford, MA).  Mobile phase A and B were 
20mM ammonium acetate in water with pH 9.0 and 100% acetonitrile 
respectively. Gradient flow: 0-3 min 85% B, 3-12 min 30% B, 12-15 min 2%B, 15-
16 min 85% B followed by re-equilibration till the end of the gradient 23 min to the 
initial starting condition of 85% B. Flow rate of the solvents used for analysis is 
0.3 ml/min. The injection volume was 10µL. 
Statistical Analysis 
For serum metabolomics, Agilent Mass Hunter Workstation Software 
Quantitative Analysis was used for manual review of chromatograms, and peak 
area was integrated based on the retention time. The normalization of each 
metabolite peak area was done relative to the peak area of the spiked internal 
standard, and then the data were log2 transformed. 
Other statistical analyses were performed with GraphPad Prism Version 
8.1.1 for Mac (GraphPad Software). Data presented are mean (± SEM) or box 
and whisker plots with individual points representing biological replicates. One-
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way ANOVA was used for multiple group analyses and two-way ANOVA was 
used for significance across multiple variables. Significance differences between 
body weight curves were determined by non-parametric one-way ANOVA with a 
Dunn’s test. Linear regression analysis was used for correlation analyses. A p 
value ≤ 0.05 was considered statistically significant. 
 
4.4 RESULTS 
Loss of endocannabinoid signaling through CB1 promotes resistance to DIO. 
To study the role of the ECS in modulating HFD-induced obesity, 
metabolic inflammation, and gut microbial dysbiosis, we fed 6-8-week-old male 
wild-type (WT) C57Bl/6J, CB1-/-, and CB2 -/- mice with HFD (60% kcal fat) or 
control LFD (10% kcal fat) for 16 weeks while monitoring DIO development. CB1-
/- mice have been previously characterized to display a delayed obesity 
phenotype whereas HFD-induced DIO in CB2-/- has not been previously reported 
to our knowledge (Ravinet Trillou et al., 2004). To validate our experimental 
model, body weight growth was monitored weekly (Figures 4.1A-4.1C). 
Consistent with previous reports, CB1-/- mice were resistant to HFD-induced 
weight gain when compared to CB1-/- mice fed LFD (Figure 4.1B). Conversely, 
HFD-fed WT and CB2-/- mice displayed significant weight gain versus LFD-fed 
mice over 16 weeks of diet (Figures 4.1A & 4.1C). The mean final weights 
expressed as a percent of starting weight in WT, CB1-/-, and CB2-/- mice fed LFD 
were 131.2%, 124.6%, and 148.0%, respectively (Figure 4.1D). WT, CB1-/-, and 
CB2-/- mice fed HFD averaged 201.8%, 163.3%, and 205.0% their starting 
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weight, respectively (Figure 4.1D). The differences in final body weight percent 
between LFD- and HFD-fed mice within each genotype were 70.6% for WT, 
38.7% for CB1-/-, and 57.0% for CB2-/- (Figure 4.1D). Food intake was measured 
weekly and showed that HFD- versus LFD-fed WT and CB2-/- mice displayed 
hedonic polyphagia while HFD-fed CB1-/- consumed similar calories to LFD-fed 
CB1-/- (Figure 4.1E). Thus, a WT pair-fed control group (WT HFD PF CB1-/-) was 
used to control for differences in feeding behavior in CB1-/- mice. The WT mice 
that were pair-fed to CB1-/- HFD mice displayed body weight growth similar to 
CB1-/- HFD mice (Figures 4.1B & 4.1D). DEXA body composition measurements 
revealed weight gain was consistent with predominantly increased adiposity, 
although WT and CB2-/- also had significant increases in lean mass after 16 
weeks of diet (Figures 4.1G-4.1I). In addition, HFD feeding caused elevated liver 
weights in WT and CB2-/- mice but not in CB1-/- mice, which indicated that CB1-/- 
mice might also be resistant to obesity-induced hepatosteatosis (Figure 4.2A). 
When evaluating feed efficiency, we found that HFD-fed mice of all genotypes 
gained more body weight per kcal consumed versus LFD-fed mice (Figure 4.1F). 
Still, CB1-/- HFD mice gained less weight per kcal consumed versus both WT 
HFD and CB2-/- HFD, which indicated enhanced energy expenditure in CB-/- mice 
(Figure 4.1F). H&E staining of interscapular brown adipose tissue further 
supported enhanced energy expenditure in CB1-/- mice because they maintained 
similar mitochondria to lipid ratios in HFD- versus LFD-fed mice, while WT and 
CB2-/- displayed increased lipid accumulation after HFD-feeding, that was more 
pronounced in CB2-/- mice (Figure 4.2B).  
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To evaluate the development of obesity-associated glucose intolerance 
and insulin resistance we performed oral glucose tolerance tests and calculated 
HOMA-IR. HFD-fed mice of all genotypes displayed signs of glucose intolerance 
versus their LFD-fed counterparts after 16 weeks of diet, although to a lesser 
extent in CB1-/- mice (Figures 4.1J & 4.1K). Furthermore, the development of 
HFD-induced glucose intolerance was delayed in CB1-/- versus WT and CB2-/- 
mice, as glucose intolerance was not observed until 16 weeks on HFD in CB1-/- 
mice, whereas CB2-/- mice developed intolerance after 8 weeks of HFD and WT 
mice after 12 weeks of HFD (Figure 4.2C). Further assessments of fasting 
glucose, insulin, and HOMA-IR revealed that HFD-fed CB1-/- mice maintained 
insulin sensitivity after 16 weeks of feeding while HFD-fed WT and CB2-/- mice 
became insulin resistant (Figures 4.1L-4.1M). Together these data indicate CB1-/- 
mice are resistant, whereas WT and CB2-/- mice are prone to development of 
HFD-induced obesity and metabolic impairments. 
Endocannabinoid signaling regulates obesity-induced inflammation.  
 A hallmark of the obese state is inflammation in metabolic tissues such as 
the adipose tissue. Growth in adiposity triggers infiltration of pro-inflammatory 
immune cells into the adipose tissue, a majority of which are M1 macrophages 
that produce pro-inflammatory cytokines and chemokines that promote insulin 
resistance (Lumeng et al., 2007). To determine the role of the ECS in ATM 
polarization, we isolated stromal vascular fractions (SVF) from epididymal fat of 
mice after 16 weeks of diet and performed immunophenotyping by flow 
cytometry. Increased ATM infiltration was observed in WT HFD mice versus WT 
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LFD mice as well as in CB2-/- HFD versus CB2-/- LFD (Figure 4.3A). Interestingly, 
CB1-/- mice were resistant to HFD-induced ATM infiltration even though HFD-fed 
CB1-/- mice had increased epididymal fat mass when compared to CB1-/- LFD 
(Figures 4.3A & 4.3B). ATM count per gram of adipose tissue was also less in 
CB1-/- HFD versus both WT HFD and CB2-/- HFD (Figure 4.3C). Furthermore, 
increased ATM infiltration coincided with an increase in ATM CD11c expression 
in WT and CB2-/- mice, indicating that the infiltrating ATMs were predominantly 
M1 macrophages (Figures 4.3A & 4.3D). All together, beneficial effects on 
adipose inflammation in CB1-/- mice was found to be primarily an effect of 
decreased appetite as ATM inflammation in WT HFDPF CB1-/- mice was similar to 
CB1-/- HFD mice (Figures 4.3A-4.3D). 
 Next, to study the role of the ECS in gut immunity we performed flow 
cytometry on lamina propria mononuclear cells (LPMCs) from the ceca-colons of 
mice after 16 weeks of diet. We found that HFD feeding in WT and CB2-/- mice 
promoted infiltration of CD45+ leukocytes into the lamina propria (Figure 4.3E). 
Immune infiltrates included CD4+T-bet+ and CD4+LAP+ populations that have 
been previously reported to be associated with irritable bowel diseases (Figures 
4.4A & 4.4B) (D’Ambrosio et al., 2016; Neurath et al., 2002). Alternatively, CB1-/- 
HFD mice maintained CD45+ populations similar to CB1-/- LFD mice indicating 
resistance to HFD-induced intestinal inflammation in mice lacking CB1, although 
WT pair-fed mice had further reductions in CD45+ cells (Figure 4.3E). CB1-/- also 
did not experience HFD-induced intestinal permeability as HFD-fed WT and CB2-
/- mice had elevated gut leakage shown by increased circulating FITC-dextran 
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and LPS, respectively (Figure 4.4C & 4.4D). Of note, CB2-/- HFD mice had higher 
percentages of CD45+ cells than WT HFD and CB1-/- HFD mice, indicating that 
loss of CB2 worsens intestinal inflammation (Figure 4.3E). Furthermore, we 
investigated the short chain fatty acid (SCFA) profile of cecal content because 
SCFAs, particularly butyrate, are associated with beneficial effects of microbiota 
(Baxter et al., 2019). Interestingly, we found that while cecal butyrate was 
downregulated in HFD- versus LFD-fed WT mice and trended less in HFD- 
versus LFD-fed CB2-/- mice, concentration remained consistent in CB1-/- mice 
between diets (Figure 4.3F). CB1-/- HFD mice also had more butyrate versus WT 
pair-fed mice, which hinted that CB1-/- mice might have an improved microbiota 
profile that may contribute to improved obesity parameters (Figure 4.3F). 
To further investigate the inflammatory status of mice after 16 weeks of 
purified diet, we performed flow cytometry on splenocytes for T cell subsets and 
butyrate is known to promote regulatory T cell (Treg) differentiation (Furusawa et 
al., 2013). We found that LFD- and HFD-fed CB1-/- mice had elevated levels of 
Foxp3+ Tregs in the spleen versus other genotypes and the pair-fed control 
(Figure 4.3G). Together, our data from various tissues indicated that CB1-/- 
suppresses HFD-induced inflammation through beneficial effects of caloric 
restriction and Treg-mediated immunosuppression, and may improve intestinal 
immunity and microbial dysbiosis that is associated with obesity. 
Non-functional CB1 alters susceptibility to HFD-induced intestinal dysbiosis. 
 Many reports indicate that obesity is associated with altered gut microbiota 
that influence host processes such as metabolism and inflammation, promoting 
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intestinal dysbiosis (Sonnenburg and Bäckhed, 2016). To identify alterations in 
gut microbiota in our receptor knockout model we performed predictive 
metagenomics by 16S rRNA gene sequencing. Stool DNA was isolated before 
(Baseline, “BL”) and after 16 weeks of purified diet feeding and used for 16S V3-
V4 amplicon sequencing. We found that baseline alpha-diversity was greater 
within microbiotas of CB1-/- and CB2-/- versus WT mice (Figure 4.5A). Sixteen 
weeks of purified diet reduced alpha diversity in all genotypes but to a lesser 
extent in CB1-/- mice (Figure 4.5A). Beta-diversity principle component analysis 
(PCoA) showed distinct clustering of the groups (Figure 4.5B). Differences in 
principle components PC1 and PC3 could be mostly explained by genotype and 
husbandry practices. At baseline, the CB1-/- and CB2-/- clusters were more similar 
to each other while the WT mice were more different (Figure 4.5B). Purified diet 
feeding shifted the gut microbiota composition of all genotypes upward on PC2, 
though to a lesser extent in LFD- versus HFD-fed mice of all genotypes. 
Interestingly, CB1-/- HFD mice showed a similar shift as CB1-/- LFD mice because 
their group clusters overlapped (Figure 4.5B).  
At the phyla level of taxonomy, baseline microbiota compositions were 
significantly altered amongst the genotypes as WT mice had a greater Firmicutes 
to Bacteroidetes ratio than both the CB1-/- and CB2-/- mice (Figures 4.5C,  4.5E, 
& 4.6). Verrucomicrobia were also present at baseline in WT but not in CB1-/- or 
CB2-/- mice. The baseline microbiota composition of CB1-/- and CB2-/- showed a 
lot of similarity, however CB1-/- had more TM7, while CB2-/- had more 
Proteobacteria (Figures 4.5C, 4.5E, & 4.6). HFD feeding in WT mice decreased 
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Bacteroidetes and coincided with a bloom in the Verrucomicrobia phyla, which is 
comprised of the species Akkermansia muciniphila, and whose abundance was 
similar between ad libitum-fed and pair-fed control groups (Figures 4.5C, 4.5E, & 
4.6). Microbiota composition in CB1-/- showed little change at the phyla level after 
16 weeks of LFD or HFD, but CB1-/- HFD mice had greater abundance of 
Deferribacteres (comprised solely of the murine commensal Mucispirillum 
schaedleri) and TM7 (comprised of unclassified F16) than HFD-fed mice of other 
genotypes (Figure 4.5C, 4.5E, & 4.6).  Similar to WT mice, CB2-/- mice 
experienced HFD-induced reduction in Bacteroidetes, but instead coincided with 
expansion of Proteobacteria (Figures 4.5C & 4.5E).  
Microbiota transfer between WT and CB1-/- mice does not alter obesity 
susceptibility. 
Given that CB1-/- mice were resistant to HFD-induced gut microbial 
changes, we asked whether their microbiota composition could also directly 
confer resistance to DIO development in WT mice, or if WT HFD feces transfer 
could accelerate DIO development in CB1-/- mice. We used co-housing and fecal 
microbiota transplant (FMT) experiments to transfer microbial populations 
between genotypes then challenged the mice with HFD feeding. Co-housing has 
been shown to lead to continual seeding of microbiota between animals (Blanton 
et al., 2016). We first placed naïve C57BL6 WT and CB1-/- into 2 mice per cage 
that were separated by genotype (Separate-housing) or co-housed between 
genotypes (Figure 4.7A). Mice continued a standard chow diet for 10 days to 
promote microbiota transfer through coprophagy then challenged with 16 weeks 
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of HFD. Body weight growth curves demonstrated that co-housing did not alter 
susceptibility to DIO development because weight gain was similar between 
separate- and co-housed mice of each genotype (Figure 4.7B). Co-housing also 
did not affect body composition or adipose inflammation (Figures 4.8A-4.8C). We 
next sequenced 16S V3-V4 rRNA gene regions of stool DNA to confirm microbial 
transfer in co-housed mice. Stool samples were collected after 10 days of co-
housing but before HFD (Pre/Baseline) and again after 16 weeks of HFD (Post). 
In separately housed groups, CB1-/- mice again had greater alpha diversity at 
baseline versus WT mice (Figure 4.7C). Co-housing of WT with CB1-/- increased 
alpha diversity of WT mice (Figure 4.7C). Sixteen weeks of HFD led to minimal 
changes in alpha-diversity versus baseline measures (Figure 4.7C). Principle 
component analysis of beta diversity revealed that just 10 days of co-housing of 
mice could shift WT microbiotas towards the dominant CB1-/- microbiota 
composition, while separately housed WT mice maintained a distinct microbiota 
profile (Figure 4.7D). Interestingly, CB1-/- mice were resistant to microbial 
alterations regardless of housing conditions (Figure 4.7D). At the phyla level of 
taxonomy, similar trends were seen in separately housed groups as shown in 
Figure 4.5 (i.e. HFD induced decreased Bacteroidetes and increased 
Verrucomicrobia in WT mice whereas CB1-/- mice were resistant to microbial 
changes) (Figure 4.7E). Co-housed WT and CB1-/- mice showed microbiota 
compositions very similar to separately housed CB1-/- mice; however, the CB1-/- 
microbiotas remained distinctly clustered of co-housed WT mice (Figure 4.7D). 
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Phyla level and genera level microbiota profiles of the individual mice are 
represented in Figures 4.8D & 4.8E.  
In addition to the co-housing experiment, we performed a fecal microbiota 
transfer (FMT) experiment in antibiotic (Abx) treated mice. C57BL6 WT mice 
were treated with Abx in drinking water for 4 weeks and maintained on standard 
chow diet in autoclaved cages to deplete their microbiota (Figure 4.9A). Abx-
treated mice were then placed in dirty donor cages 4 days prior to FMT gavage 
of donor feces (Figure 4.9A). Microbiota depletion after 4 weeks of Abx was 
confirmed by stool culture and bacterial qRT-PCR (Figures 4.9B & 4.9C). As a 
result, FMT from CB1-/- to WT mice did not confer resistance to acute weight gain 
after HFD challenge (Figure 4.9D).  
Together our co-housing and FMT experiments indicated that transfer of 
CB1-/- feces into WT mice did not alter susceptibility to DIO development, albeit 
complete microbial transfer was not achieved. Thus CB1-/- mice may likely be 
resistant to HFD-induced intestinal dysbiosis due to host microbial defense 
mechanisms or the rare microbes that are maintained in the dominant CB1-/- 
microbiota. 
Blockade of CB1 receptors reverses DIO and shifts the gut microbiota 
composition. 
 To further understand how CB1 regulates microbiota and host interactions 
we used a DIO intervention model with the CB1 antagonist AM251. CB1 
antagonists are well-known to induce weight loss, reduce inflammation, and 
improve glucose metabolism however studies on the interactions with the gut 
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microbiota are few to date (Mehrpouya-Bahrami et al., 2017, 2019; Miranda et 
al., 2019). Male C57BL6 mice were fed LFD or HFD for 12 weeks prior to 
intervention. AM251 was administered daily for 4 weeks at a dose of 10mg/kg by 
oral gavage. Non-treated mice received Vehicle (Veh) gavages. In addition, a 
pair-fed control was included to control for decreased appetite observed in 
AM251-treated mice. Body weight was monitored during the 4-week intervention 
and showed that LFD+Veh mice maintained initial weight while HFD+Veh mice 
gained weight (Figure 4.10A). HFD+AM251 mice quickly lost weight during the 
first week of treatment and maintained weight loss for the remainder of the 
experiment (Figure 4.10A). Weight loss coincided with suppressed appetite 
(Figure 4.10B). Interestingly, the HFD-Pair-fed mice did not loose as much 
weight and eventually gained back all their starting weight (Figure 4.10A). 
Overall, body weight curves were significantly different in all of the experimental 
groups (Figure 4.10A). DEXA fat percentage measurements showed that HFD-
fed groups had equivalent Pre treatment (Tx) fat mass that was significantly 
greater than LFD+Veh mice (Figure 4.10C). Post 4 weeks of treatment, 
HFD+Veh and HFD-Pair-fed mice gained, whereas LFD+Veh mice maintained, 
and HFD+AM251 mice lost fat percentage versus Pre Tx (Figure 4.10C). At the 
Post Tx timepoint fat percentage was significantly less in HFD+AM251 treated 
mice versus both HFD+Veh and HFD-Pair-fed, though pair-fed mice displayed an 
intermediate fat percentage (Figures 4.10C & 4.10D). Fasting blood glucose was 
also significantly reduced in HFD+AM251 mice versus both HFD+Veh and HFD-
Pair-fed mice (Figure 4.10E). In addition, DIO-induced inflammation was reduced 
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in adipose tissue and the ccLP (Figures 4.10F-4.10H). Furthermore intestinal 
barrier integrity appeared improved with treatment, as HFD+AM251 mice had 
reduced plasma LPS concentrations versus HFD+Veh mice (Figure 4.10I).  
 When investigating microbiota composition Pre Tx and Post Tx by 16s V3-
V4 rRNA gene sequencing, we observed little alterations in alpha diversity 
(Figure 4.10J). Beta diversity was similar Pre Tx in all the HFD-fed groups but 
distinct from LFD+Veh (Figure 4.10K). Post Tx, HFD+AM251 microbiota 
composition shifted on PC3 similarly to LFD+Veh, while HFD+Veh and HFD-Pair-
fed clustered closer together (Figure 4.10K). At the phyla level, Post Tx 
HFD+AM251 microbiotas more closely resembled those of LFD+Veh (Figurse 
4.10L & 4.11A). Interestingly, HFD+AM251 mice had increased abundance of 
genera belonging to the Clostridiales order (Figures 4.11B & 4.11C). This trend 
was similar to that observed in WT LFD versus WT HFD mice shown in Figure 
4.6C indicating that AM251 treatment in DIO WT mice shifts microbiota 
composition towards a lean profile and may have beneficial effects on DIO. 
CB1 alters transcriptome profiles of intestinal epithelial cells relating to host 
defense. 
 To investigate potential host microbial defense mechanisms we performed 
transcriptome analyses on EpCAM+ intestinal epithelial cells (IEC) isolated from 
the ceca: colons of mice from the both the CB receptor knockout model and 
AM251 DIO intervention model (Figures 4.12A-4.12D). CB1-/- HFD IECs were 
found to have 188 genes differentially expressed (Fold change ≥ ± 1.5) versus all 
other HFD-fed groups (WT HFD, WT HFDPF CB1-/-, and CB2-/- HFD), and are 
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displayed in a heatmap (Figure 4.12A). HFD+AM251 IECs displayed 203 
differentially expressed genes versus both HFD+Veh and HFD-Pair-fed (Figure 
4.12B). When comparing those genes that were similarly dysregulated in CB1-/- 
HFD and HFD+AM251 IECs, we identified 15 genes that are likely regulated by 
appetite-independent CB1 knockout or antagonism (Figure 4.12C). These 
include upregulation of antimicrobial peptide (AMP) genes Lgals2, Lyz2, and 
Reg3b (Figure 4.12D). Ingenuity Pathway Analysis (IPA, Qiagen) showed that 
the upregulated genes related to an increased antimicrobial response and 
decreased inflammatory response with increased cellular viability and cell-cell 
adhesion (Figure 4.12E). Expression of Lys2 was found to be reproducibly 
induced by qRT-PCR validation (Figure 4.12F). Together, transcriptome data 
from our models indicated that CB1 may regulate intestinal integrity and host 
antimicrobial defense through modulation of AMP gene expression. 
CB1 regulates host and microbiota carbohydrate metabolism. 
 We next investigated potential gut microbiota metabolic pathways that are 
affected following CB1 knockout/blockade, which may contribute to altered host 
metabolism. To first identify host metabolic pathways affected, we performed 
tricarboxylic acid cycle (TCA)-targeted metabolomics on fasting serum samples 
from WT, CB1-/-, or CB2-/- mice fed LFD or HFD for 16 weeks. Of the 108 
metabolites detected, 33 were differentially expressed in CB1-/- HFD versus at 
least one other HFD-fed group and whose mean expression relative to internal 
control are displayed in a heatmap (Figure 4.13A). ANOVA analyses further 
identified metabolites that were similarly regulated in CB1-/- HFD versus both WT 
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HFD and CB2-/- HFD and are identified by bold text* (Figure 4.13A). Furthermore, 
4 metabolites that were similarly regulated in CB1-/- HFD versus all three HFD-
fed groups (WT HFD, WT HFDPF CB1-/-, and CB2-/- HFD) are denoted by bold 
text** (Figure 4.13A). MetaboAnalyst pathway analysis of the host metabolic 
pathways affected by these 4 differentially expressed metabolites identified 
overlap with TCA cycle, glycolysis/gluconeogenesis, and alanine, aspartate, and 
glutamate metabolism (Figure 4.13B). The two metabolites that correlated with 
these pathways, were ketoglutarate and phosphoenolpyruvate (PEP), and were 
downregulated in CB1-/- HFD mice (Figures 4.13C & 4.13D). Furthermore, we 
looked to microbiota metabolic pathways regulated by CB1 through PICRUSt 
analysis of 16S sequencing data. We found that the microbial functional 
pathways of glycolysis: gluconeogenesis, phosphotransferase system (PTS), and 
fructose and mannose metabolism were upregulated in HFD- vs. LFD-fed mice of 
WT and CB2-/- genotypes but unchanged or downregulated with CB1-/- HFD 
(Figures 4.13E-4.13G).  
We looked further at the reproducibility of this trend in our co-housing and 
AM251 DIO intervention model. In the co-housing model, glycolysis: 
gluconeogenesis, PTS, and fructose and mannose metabolism were again 
downregulated in separately housed HFD-fed CB1-/- versus WT mice (Figures 
4.13H-4.13J). Interestingly, co-housed CB1-/- mice maintained downregulation of 
PTS, and fructose and mannose metabolism pathways versus co-housed WT 
mice, which indicated that regulation of these pathways were specific to CB1-/- 
mice and may result from the rare microbes that remained differentially 
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expressed in co-housed CB1-/- mice versus co-housed WT mice (Figures 4.13I 
and 4.13J). PEP is also the phosphate donor for the PTS system, which imports 
sugars such as fructose and mannose into bacterial cells, and PEP was greatly 
reduced in CB1-/- HFD mice versus all other groups (Figure 4.13D). In addition, 
downregulation of these microbial metabolic pathways appeared to be dependent 
on CB1 signaling as blockade of this receptor in DIO mice also reduced microbial 
gene counts of glycolysis: gluconeogenesis, PTS, and fructose and mannose 
metabolism pathways versus DIO vehicle and pair-fed controls (Figures 4.13K-
4.13M). Together these data indicated that CB1 signaling activation promotes 
carbohydrate metabolism pathways that may increase energy harvest of 
intestinal microbiota and contribute to body weight gain. 
Microbiota sugar metabolism positively correlates with body weight. 
Given that we had downregulation of serum metabolites and microbial 
metabolic pathways related to sugar metabolism, we performed linear regression 
analyses to correlate microbial metabolic pathways with host obesity parameters 
including fasting blood glucose and end-point body weight. Data from mice of 
receptor knockout, co-housing, and DIO intervention models were pooled for 
analyses (Figure 4.14A). Fasting blood glucose measurements were not 
associated with abundance of glycolysis: gluconeogenesis, PTS, or fructose and 
mannose metabolism pathways in microbiota, indicating that host substrate 
availability may not be responsible for altered expression of these pathways 
(Figures 4.14B-4.14D). Excitingly, these metabolic pathways positively correlated 
with body weight, which supports the overall conclusion that increases in these 
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microbial pathways contribute to increased capacity for energy harvest in DIO 
microbiomes (Figures 4.14E-4.14G). In particular, enrichment of PTS and 
fructose and mannose metabolism PICRUSt pathways in human obesity are 
supported in previous publications (Hou et al., 2017; Liu et al., 2017).  
 
4.5 DISCUSSION 
 The anti-obesity effects of CB1-/- and CB1 antagonism are well 
documented yet the anti-obesity, microbiota-related mechanisms are not well 
understood. Additionally, the role of CB2 in obesity-related processes has not 
been widely investigated, but is important for understanding ECS regulation of 
immunometabolism. In this study, we used multiple DIO models to identify novel 
host: microbial interactions regulated by cannabinoid receptor signaling that 
could form the basis for microbiota-related therapeutics.  
 First, we performed HFD-induced obesity studies in CB1 and CB2 
knockout mice. In accordance with previous reports, CB1-/- mice were resistant to 
HFD-induced weight gain, adipose expansion, and development of insulin 
resistance versus WT and CB2-/- mice. These effects appeared to be largely due 
to decreased calorie intake in CB1-/- mice; however, energy intake-independent 
benefits observed in CB1-/- HFD mice included decreased fasting blood glucose 
that was similar to lean mice. It is also noteworthy that anti-obesity effects 
observed in the WT HFDPF CB1-/- pair-fed control group could have been in part 
due to intermittent fasting because this group ate all the supplied food each day 
and likely experienced significant amounts of time without food access between 
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daily feedings. The anti-obesity effects of intermittent fasting have been 
previously documented, therefore it was challenging to control for appetite in our 
model (Li et al., 2017). Indeed, the DIO intervention model with AM251 
demonstrated some anti-obesity effects of CB1 blockade beyond the effect of 
appetite restriction including increased weight loss, decreased ATM percentage, 
and decreased fasting blood glucose. We also report here for the first time the 
development of HFD-induced obesity in CB2-/- mice. Body weight growth and 
body composition of CB2-/- HFD mice was similar to WT HFD mice, however 
CB2-/- HFD mice developed glucose intolerance earlier and had more lipid 
accumulation in brown adipose tissue and therefore, were more susceptible to 
DIO than WT mice. These data confirm previous anti-obesity effects of CB1-/- and 
identify the importance of CB2 signaling in metabolic regulation. 
 Inflammation in adipose tissue is a hallmark of the obese state that can be 
triggered by metabolic stress that activates innate immunity due to the release of 
damage-associated molecular patterns (Vandanmagsar et al., 2011). In addition, 
alterations of obese microbiome increase circulating LPS levels that activate 
cytokine production and promote metabolic endotoxemia that exacerbates 
chronic inflammation and metabolic dysfunction (Cani et al., 2007, 2008).  In the 
current study, we found that adipose tissue, intestinal inflammation, and intestinal 
barrier function improved in CB1-/- mice primarily through beneficial effects of 
reduced caloric intake. Furthermore, CB1-/- mice showed HFD-induced increases 
in the anti-inflammatory microbial metabolite butyrate, which could have 
contributed to their increased induction of Tregs overall decreased inflammatory 
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state, as previously shown in other models (Furusawa et al., 2013). Together 
these data indicated that CB1-/- mice were resistant to the exacerbation of 
metabolic inflammation that arises from gut microbiota-mediated intestinal 
dysbiosis. Furthermore, elevated intestinal inflammation and leakage in DIO CB2-
/- mice demonstrates an important role for CB2 activation in maintaining gut 
homeostasis. Our group has previously shown therapeutic value of the CB2 
agonist JWH-133 in the IL10-/- murine model of chronic colitis (Singh et al., 2012). 
More recently we have shown that administration of the phytocannabinoid, delta-
9-tetrahydrocannabinol, reduces severity of multiple murine colitis models 
through immune-mediated effects of CB2 activation (data not shown, Becker et 
al., in submission). Overall, the opposing observations of intestinal barrier 
function between DIO CB1-/- and CB2-/- mice suggested that in normal mice, 
increased endocannabinoid signaling through CB2 is beneficial in maintaining gut 
homeostasis and that this may have contributed to the improvements observed in 
CB1-/- mice.  
 When we characterized the microbiota composition of WT, CB1-/-, and 
CB2-/- mice before and after 16 weeks of diet we noticed many significant 
alterations but markedly, CB1-/- mice were resistant to HFD-induced alterations in 
microbiota composition. This suggested that either their dominant microbiota 
composition could be protective against DIO development, or alternatively, 
reduced DIO development in CB1-/- could have been responsible for these 
reduced alterations in microbiota profile. Surprisingly, A. muciniphila was absent 
in CB1-/- and CB2-/- microbiotas. This bacterium has been reported to improve 
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obesity and metabolism by increasing intestinal levels of the endocannabinoids, 
2-Oleoylglycerol and 2-Arachidonylglycerol, which improve barrier function and 
decrease inflammation (Everard et al., 2013; Plovier et al., 2017). It is possible 
that endocannabinoid signaling through CB1 and CB2 is necessary for the 
survival of A. muciniphila, or A. muciniphila could be out-competed by other 
microbes present in CB1-/- and CB2-/- microbiotas, but the mechanisms involved 
require further investigation. Also unexpectedly, we observed a substantial 
increase of A. muciniphila in WT HFD versus WT LFD mice, suggesting that 
overgrowth of this bacterium could be detrimental in the context of DIO. On the 
whole, it is evident that the mechanisms of A. muciniphila regulation of 
metabolism are complex and context-dependent. Other differences observed in 
CB1-/- HFD mice included increased abundances of M. schaedleri, and 
unclassified F16. M. schaedleri is a border dwelling, mucus-degrading 
commensal that protects against Salmonella-induced colitis in mice, and has 
been shown to thrive in niche established by extrathymically generated Tregs 
(Campbell et al., 2018; Herp et al., 2019). The F16 family has been reported to 
be enriched in lean male mice; however, the precise functions of this family are 
currently unknown (Qin et al., 2018). Furthermore, CB1-/- versus CB2-/- mice had 
less abundance of the phylum Proteobacteria that contains many pathogenic 
bacteria and whose abundance is enriched in human obesity (Méndez-Salazar et 
al., 2018). Overall, the gut microbiome of CB1-/- mice displayed a dominant 
phenotype that was resistant to changes associated with obesity, and enriched in 
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protective commensals that likely maintain barrier function and immune 
homeostasis. 
 To better understand the role of the CB1-/- microbiome in protecting 
against DIO, we performed co-housing and FMT experiments in WT and CB1-/- 
mice. This was especially important for data interpretation inasmuch as baseline 
microbiota composition of WT and CB1-/- were dramatically different, and co-
housing is an effective way to standardize microbiota, though the mucosal 
microbiota can be difficult to normalize (Robertson et al., 2019). Remarkably, 
only 10 days of co-housing was able to shift the WT stool microbiota composition 
towards a CB1-/- profile, yet the CB1-/- composition did not change between co-
housed and separately housed mice. This further demonstrated that CB1-/- mice 
have a dominant microbiota composition whose colonization is firmly established. 
Despite similar microbiome compositions in WT and CB1-/- mice, DIO 
development was not altered indicating that the beneficial effects of CB1-/- are 
due to host-driven mechanisms or the small community of microbes that 
remained differentially expressed after co-housing.  
 We also investigated the microbiome composition of DIO mice treated with 
the CB1 antagonist AM251. In accordance with a previous report from our lab, 
CB1 antagonist treatment attenuated obesity, decreased inflammation in adipose 
tissue and cecum: colon, and reduced metabolic endotoxemia (Mehrpouya-
Bahrami et al., 2017). The gut microbiota shift with AM251 treatment also 
showed a change similar to that of lean control mice. These data confirmed that 
CB1-/- or CB1 blockade have beneficial effects on the DIO gut microbiota 
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composition, yet from our co-housing and FMT experiments we found that the 
microbiota composition is largely dispensable for the improved obesity 
phenotype. Therefore, we further investigated host- and microbiota-mediated 
mechanisms of intestinal barrier function and metabolism, and correlated the 
findings between our receptor knockout and intervention models.  
 To accomplish this, we performed transcriptomics on EpCAM+ intestinal 
epithelial cells from ceca: colons of mice. CB1-/- and AM251 treatment altered the 
transcriptome profiles of ccIECs. Interestingly, upregulation of a few AMPs were 
observed in both models, indicating their expressions are regulated by CB1. For 
example, Lyz2 expression was reproducibly elevated in HFD+AM251 ccIECs. 
This gene encodes lysozyme 2 and lysozymes are glycosidases produced by 
Paneth cells that can directly kill bacteria by hydrolyzing peptidoglycan 
(Mukherjee and Hooper, 2015). Paneth cell production of lysozyme is decreased 
in both murine and human obesity (Guo et al., 2017; Hodin et al., 2011). This 
suggests that upregulation of Lyz2 contributes to shaping gut immunity, barrier 
integrity, and microbiota composition during CB1 knockout/blockade and 
provides protection against DIO-induced dysbiosis (Figure 4.15). 
 Next we investigated the serum metabolome and altered gut microbiota 
PICRUSt pathways to correlate changes in circulating metabolites with microbial 
processes. Most strikingly, serum PEP was reduced in CB1-/- HFD. PEP is an 
important intermediate in biochemistry involved in glycolysis: gluconeogenesis in 
organisms as well as the microbial PTS. PEP contains the highest energy 
phosphate bond found in all organisms. Phosphoenolpyruvate carboxykinase-
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mediated conversion of oxaloacetate to PEP is the rate-limiting step in 
gluconeogenesis (Nelson et al., 2008). In the PTS, PEP provides the source of 
energy for bacterial import and phosphorylation of various monosaccharides 
such as glucose, fructose, and mannose (Mahowald et al., 2009). Reduced 
levels of PEP in CB1-/- HFD mice indicated that gluconeogenesis was reduced in 
these animals. Importantly, increased PEP-dependent gluconeogenesis 
contributes to increased adiposity in human obesity (Chevalier et al., 2006). 
Furthermore, predicted PICRUSt pathways in the gut microbiota showed 
downregulation of glycolysis: gluconeogenesis, PTS, and fructose and mannose 
metabolism pathways across our various models. It was recently shown that PTS 
and fructose and mannose metabolism are enriched in obese human 
microbiomes, yet the precise mechanisms of how these pathways relate 
increased energy harvest were not investigated (Liu et al., 2017). In our model, 
correlation analysis showed that these microbial pathways are positively 
correlated with body weight gain but not fasting blood glucose measurements. 
Overall, these findings supported gut microbiota involvement in regulation of host 
obesity through CB1-dependent regulation of microbial sugar metabolism. Future 
research aimed at modulating these bacterial pathways during obesity could 
provide further insight into microbiota-mediated mechanisms of energy harvest. 
In summary, our study shows that over activation of the ECS in DIO 
impairs intestinal barrier function and promotes increased energy storage. CB1 
knockout or blockade had beneficial effects on host metabolism that was at least 
in part due to improved host intestinal barrier function, likely due to increased 
	
117 
endocannabinoid signaling through CB2, as well as downregulation of 
carbohydrate metabolic pathways in gut microbiota that together decreased 







Figure 4.1 CB1 deletion promotes resistance to DIO. 
Male C57Bl6 WT, CB1-/-, and CB2-/- mice were fed purified LFD or HFD for 16 
weeks. Body weight and composition as well as glucose metabolism were 
repeatedly analyzed during 16 weeks of diet feeding. (A-C) Body weight growth 
curves for WT (A), CB1-/- (B), and CB2-/- (C) mice over 16 weeks of diet. (D) 
Percentage of body weight gain during 16-weeks of feeding.  (E) Mean daily kcal 
consumed per mouse. N=2 experiments. (F) Feed efficiency calculated by weight 
gain per kcal consumed over 16 weeks of diet. (G) DEXA lean mass measured 
every 8 weeks of diet. (H) DEXA fat mass measured every 8 weeks of diet. (I) 
Representative DEXA scans. (J) Oral glucose tolerance test (GTT) performed 
after 16 weeks of diet. (K) Area under the curve (A.U.C) for the GTT performed in 
(J). (L) Fasting glucose measured after 16 weeks of diet. (M) Fasting insulin 
measured after 16 weeks of diet. (N) HOMA-IR measured after 16 weeks of diet. 
Data shown are mean +/- SEM or box and whisker plots with each point 
representing biological replicates. N=10 mice/group except N=5 for WT HFDPF 
CB1-/-. *p<0.05, **p<0.01, ***p,0.001 vs. LFD within each genotype (colored by 
genotype- WT: black, CB1-/-: red, CB2-/-: blue) or as indicated by a line. 
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Figure 4.2 CB1 knockout delays DIO development and glucose intolerance. 
As described in Figure 4.1, male C57Bl6 WT, CB1-/-, and CB2-/- mice were fed 
purified LFD or HFD for 16 weeks. (A) Liver wet weight after 16 weeks of diet. (B) 
Representative H&E micrographs of interscapular brown adipose tissue (BAT) 
after 16 weeks of diet.  (C) GTTs and A.U.C.s performed after 4, 8, and 12 weeks 
of diet. Data shown are mean +/- SEM or box and whisker plots with each point 
representing biological replicates. N=5 mice/group except N=3 mice/group for 
(B). *p<0.05, **p<0.01, ***p,0.001 vs. LFD within each genotype (colored by 
genotype- WT: black, CB1-/-: red, CB2-/-: blue) or as indicated by a line. 
Significance was determined by one- or two-way ANOVA. 
 





























































































































































































































Figure 4.3 Loss of CB1 suppresses HFD-induced inflammation. 
As described in Figure 4.1 legend, male C57Bl6 WT, CB1-/-, and CB2-/- mice 
were fed purified LFD or HFD for 16 weeks. Inflammation in adipose tissue, 
spleen, and cecal-colonic lamina propria was analyzed by flow cytometry. (A) 
Representative flow cytometry plots of epididymal fat ATMs and ATM-gated 
CD11c MFI. (B) Epididymal fat pad mass.  (C) Total ATMs per gram of 
epididymal adipose tissue. (D) CD11c MFI on ATMs to estimate M1 ATM 
polarization. (E) Percentage of CD45+ leukocytes in cecal-colonic lamina propria. 
(F) Concentration of butyrate in cecal content after 16 weeks of diet. (G) 
Percentage of CD4+Foxp3+ Tregs in spleen. Data shown are mean or box and 
whisker plots with each point representing biological replicates. N=5-10 
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Figure 4.4 Loss of CB1 suppresses HFD-induced intestinal inflammation 
and permeability. 
As described in Figure 1 legend, male C57Bl6 WT, CB1-/-, and CB2-/- mice were 
fed purified LFD or HFD for 16 weeks. Inflammation in cecal-colonic lamina 
propria (ccLP) was analyzed by flow cytometry. Estimates of intestinal 
permeability were assessed by FITC-dextran assay and plasma endotoxin levels. 
(A) ccLP flow cytometry gating strategy. (B) CD4+T-bet+ Th1 cell count in ccLP. 
(C) CD4+LAP+ Th cell count in ccLP. (D) FITC-dextran (4kD) in plasma. (E) LPS 
concentration in plasma. Data shown are box and whisker plots with each point 
representing biological replicates. N=3-8 mice/group. *p<0.05, **p<0.01, 



































































































































































































Figure 4.5 CB1-/- mice are resistant to HFD-induced alterations in gut 
microbiota. 
As described in Figure 4.1 legend, male C57Bl6 WT, CB1-/-, and CB2-/- mice 
were fed purified LFD or HFD for 16 weeks. Stool samples were collected pre- 
(Baseline, “BL”) and post- 16 weeks of purified diet for 16S V3-V4 rRNA gene 
sequencing. (A) Alpha diversity by Chao and Shannon indices. (B) 3D PCoA plot 
of unweighted UniFrac beta diversity. (C) Mean relative abundance of each 
bacterial phyla displayed as a pie chart per group. (D) OTU % of significantly 
altered phyla for each biological replicate. Data shown are mean (+/- SEM) or 
box and whisker plots with each point representing biological replicates. N=3-15 
mice/group. *p<0.05, **p<0.01, ***p,0.001 by one-way ANOVA. 
 































































































































































































































































































































Figure 4.6 Predictive metagenomics by 16S V3-V4 rRNA gene sequencing. 
As described in Figure 4.5 legend, stool samples were collected pre- (Baseline) 
and post- 16 weeks of purified diet for 16S V3-V4 rRNA gene sequencing.  (A) 
Phylum level abundance for each biological replicate. (B) Genus level abundance 
for each biological replicate. (C) LEfSe cladograms of enriched bacterial taxa. 
For (A-B), each bar represents one mouse’s predicted microbiota at the 





Figure 4.7 Gut microbiota composition is largely dispensable for the 
improved obesity phenotype observed in CB1-/- mice. 
Male C57Bl6 WT and CB1-/- were placed in co-housing or standard separate 
housing conditions at 6-8 weeks of age and maintained on standard chow diet for 
10 days before being placed on HFD for 16 weeks. Stool samples were collected 
after 10 days of co-housing but pre-HFD (termed “Baseline” or “Pre”) and post- 
16 weeks of HFD for 16S V3-V4 rRNA gene sequencing. (A) Experimental 
timeline and caging setup for separate- (sep) and co-housing (co).  (B) Body 
weight growth curves.  (C) Chao index alpha diversity. (D) 3D PCoA plot of 
unweighted UniFrac beta diversity.  (E) Mean relative abundance of each 
bacterial phyla displayed as a pie chart per group. Data shown are mean (+/- 
SEM). N=3-4 mice/group. ns: not significant (p>0.05) between housing conditions 






Figure 4.8 Co-housing WT and CB1-/- mice does not confer resistance to 
DIO development; however, CB1-/- maintain a dominant microbiota 
composition. 
As described in Figure 4.7 legend, mice were placed in co-housing or standard 
separate housing conditions and challenged with HFD. (A) DEXA lean and fat 
mass. (B) Epididymal ATM (CD45+CD11b+F4/80+) count per gram of fat 
measured by flow cytometry. (C) Epididymal ATM-gated CD11c MFI. (D) Phylum 
level abundance for each biological replicate. (E) Genus level abundance for 
each biological replicate. Data shown are mean +/- SEM. N=3-4 mice/group. ns: 
not significant (p>0.05) between housing conditions within each genotype, 






Figure 4.9 Transfer of CB1-/- feces does not confer resistance to DIO 
development. 
Naïve 5-week-old male C57BL6 mice were depleted of gut microbiota by 
administering antibiotics (“Abx”, 1mg/mL Bacitracin, 170ug/mL Gentamycin, 
125ug/mL Ciprofloxacin, 100ug/mL Neomycin, 100U/mL Penicillin, 100ug/mL 
Metronidazole, 100ug/mL Ceftazidime, 50ug/mL Streptomycin, 50ug/mL 
Vancomycin) in the drinking water for 4 weeks then microbiota from naïve 
C57BL6 WT and CB1-/- mice were transferred into Abx-treated recipients. The 
mice were maintained in autoclaved caging and challenged with irradiated HFD 
after fecal microbiota transfer (FMT). (A) Abx microbiota depletion and FMT 
experimental timeline. (B) Microbiota depletion validation by culturing feces on 
chocolate agar for 24h. (C) Microbiota depletion validation by qRT-PCR for 
Eubacteria (Eub) normalizd to host 18S genes. (D) Body weight growth curves 
during 3 weeks of HFD feeding. Data shown are mean +/- SEM. ns: not 
significant (p>0.05) between FMT groups by one-way ANOVA. **p<0.01, 
***p<0.001 by one-way ANOVA. For WT HFD and CB1-/- HFD, n=2 mice/group. 





Figure 4.10 DIO intervention with the CB1 antagonist AM251 reverses 
obesity, inflammation, and shifts intestinal microbiota composition. 
Male C57Bl6 mice were fed purified diets for 12-weeks prior to a 4 week DIO 
intervention with AM251. HFD-fed DIO mice were treated with AM251 (10mg/kg, 
o.g.) daily for 4 weeks. All other control groups were treated with vehicle (Veh). 
Mice were fed ad libitum, except the pair-fed group received the same amount of 
food as the HFD+AM251 group consumed daily. Stool samples were collected 
before and after treatment for 16s V3-V4 rRNA gene sequencing. (A) Body 
weight. (B) Food intake.  (C) Body fat percentage Pre- and Post- treatment (Tx) 
measured by DEXA. (D) Representative DEXA scans. (E) Fasting blood glucose 
after 4 weeks of treatment. (F) Representative flow cytometry contour plots of 
epididymal ATMs after 4 weeks of treatment. (G) CD45+CD11b+F4/80+ ATM 
percentage of SVF. (H) Cecal:colonic lamina propria (ccLP) percentage of 
CD45+ leukocytes. (I) Plasma LPS concentration after 4 weeks of treatment. (J) 
Microbiota alpha diversity by Chao index. (K) Unweighted UniFrac PCoA plot of 
beta diversity. (L) Phylum level abundance pie charts. Data shown are mean (+/- 
SEM) or box and whisker plots with each point representing biological replicates. 
For (A and C), N=9-10 mice/group. For (B), N=3 independent experiments. For 
(E-L), N=4-6 mice/group*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA 
#P<0.05 vs. Pre Tx. For (A) p<0.05 if alphabetical characters differ between the 




Figure 4.11 AM251 DIO intervetion predictive metagenomics by 16S V3-V4 
rRNA gene sequencing. 
As described in Figure 4.10 legend, stool samples were collected pre-  and post- 
4 weeks of AM251 DIO intervention for 16S V3-V4 rRNA gene sequencing. (A) 
Phylum level abundance for each biological replicate. (B) Genus level abundance 
for each biological replicate. (C) LEfSe cladograms of enriched bacterial taxa. 
For (A-B), each bar represents one mouse’s predicted microbiota at the 




Figure 4.12 CB1 regulates microbial defense in intestinal epithelial cells. 
EpCAM+ IECs were isolated from ceca: colons of mice at the conclusion of the 
CB receptor knockout and AM251 DIO intervention studies described in Figure 
4.1 and Figure 4.10 legends. (A) Heatmap of 188 differentially expressed genes 
in ccIEC of CB1-/- HFD mice versus all other HFD-fed groups. (B) Heatmap of 
203 differentially expressed genes in ccIEC of HFD+AM251 mice versus all other 
HFD-fed groups. (C) Venn diagram comparison of similarly regulated genes in 
CB1-/- HFD and HFD+AM251 mice of each DIO model. (D) Heatmap of appetite-
independent CB1 regulated genes.  (E) IPA pathway analysis of differentially 
expressed genes in panel D. (F) qRT-PCR validation of AMPs in the AM251 DIO 
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Figure 4.13 CB1 regulates host and intestinal microbiota sugar metabolism. 
As described in Figures 4.5, 4.7, and 4.10, stool DNA from the three DIO models 
(CB receptor knockout, co-housing, and AM251 intervention) were used for 16S 
predictive metagenomics. Serum TCA cycle targeted metabolomics were 
performed on fasting serum samples from the CB receptor knockout model only. 
PICRUSt analyses were performed on 16S sequencing data for all three models. 
(A) Heatmap of serum metabolites differentially expressed in CB1-/- HFD versus 
at least one other HFD-fed group. Metabolites in bold* indicates ANOVA p<0.05 
in CB1-/- HFD versus both WT HFD and CB2-/- HFD. Metabolites in bold ** 
indicates ANOVA p<0.05 in CB1-/- HFD versus all three HFD-fed groups (WT 
HFD, WT HFDPF CB1-/-, and CB2-/- HFD). (B) MetaboAnalyst pathway analysis of 
metabolic pathways affected by the bold metabolites in panel A. (C) Relative 
abundance of ketoglutarate versus internal control in fasting serum. (D) Relative 
abundance of phosphoenolpyruvate (PEP) versus internal control in fasting 
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gluconeogenesis pathways by PICRUSt analysis. (F, I, L) 16s % gene counts 
relating to phosphotransferase system processes (PTS) by PICRUSt analysis. 
(G, J, M) Gut microbial % gene counts relating to fructose and mannose 
metabolism by PICRUSt analysis. Data shown are mean or box and whisker 
plots with each point representing biological replicates. N=3-6 mice/group. 





Figure 4.14 Microbiota sugar metabolic pathways correlate with body 
weight gain. 
As described and shown in Figure 4.13, PICRUSt predictions for microbial 
pathways relating to sugar metabolism were downregulated with CB1 knockout 
(KO) or knockdown. Linear regression analyses were performed to correlate the 
metabolic pathways with host fasting glucose concentration and endpoint body 
weight. (A) Key for groups displayed in B-G. (B-D) Correlation of microbial 
pathways with fasting blood glucose. (E-G) Correlation of microbial pathways 
with body weight. Represented are data points for individual mice. 
  













































































































































Figure 4.15 CB1 blockade improves DIO-induced intestinal dysbiosis. 
During obesity, gut microbial dysbiosis promotes intestinal permeability, 
inflammation, barrier dysfunction, and metabolic endotoxemia. CB1 blockade 
improves barrier integrity due to antimicrobial response and production of 
antimicrobial peptides such as Lysozyme 2 by Paneth cells. Immune surveillance 






In this dissertation, mechanisms involved in ECS regulation of obesity-
induced inflammation were investigated, and included epigenetic regulation of 
ATMs, as well as gut microbiota: host interactions. 
We first characterized miRNA expression profiles of ATMs isolated from 
lean and HFD-induced obese mice. Increased ECS activation and ATM 
inflammation is observed in obesity, yet miRNA expression profiles of ATMs were 
not yet established.  Interestingly, downregulation of the miR-30 family led to 
induction of DLL4-Notch signaling-induced ATM M1 polarization and pro-
inflammatory cytokine production. Furthermore, miR-30 expression was at least 
in part regulated by DNA methylation. This study identified miR-30 as a potential 
therapeutic modality for the treatment of obesity and prevention of associated 
metabolic impairments. 
Secondly, we used a DIO intervention model whereby obese mice were 
treated with the CB1 antagonist AM251. Investigation of miRNA profiles in ATMs 
revealed that expression of miR-30e-5p was upregulated following CB1 
blockade, independent of reduced calorie intake. Subsequently, DLL4-Notch 
signaling-induced ATM M1 polarization was reduced. In addition, other DLL4-
Notch signaling-associated parameters were altered as a result of CB1 blockade. 
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These included a reduction in adipocyte size, decreased inflammatory 
cytokine/chemokine expression in ATMs, and a reduced Th1 inflammatory 
response. Furthermore, AM251 treatment of macrophages suppressed their 
capability to promote a Th1 response through regulation of DLL4. This study 
demonstrated that upregulation of miR-30e-5p in ATMs following CB1 blockade 
has anti-inflammatory and anti-obesity effects, which further support the 
therapeutic potential of this miRNA for obesity treatment.  
Lastly, we investigated gut microbiota and intestinal immunity during DIO 
in mice lacking functional cannabinoid receptors as well as in AM251-treated DIO 
mice. Markedly, we found that resistance to DIO development in CB1-/- mice 
coincided with resistance to alterations in the gut microbiome. CB2-/- mice also 
experienced accelerated obesity development and elevated abundance of 
pathogenic bacteria in their gut microbiomes versus wild-type controls. We 
further investigated the beneficial effects of CB1-/- microbiota by performing co-
housing and fecal microbiota transfer and found that the composition of microbes 
was largely dispensable for improved obesity phenotype, yet some rare microbes 
remained differentially expressed after co-housing. This led to the conclusion that 
CB1-/- mice have a dominant microbiome that is firmly established, which may 
contribute to metabolic homeostasis. DIO mice treated with AM251 experienced 
a shift in microbiota profile similar to lean mice. Further investigation of 
interactions between host and gut microbiota revealed that CB1 regulates 
antimicrobial peptide production in intestinal epithelial cells. Furthermore, CB1 
regulated sugar metabolic pathways in microbiota that correlate with body weight 
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gain. This study identified novel pathways regulated by CB1 that are involved in 
intestinal immunity and gut microbiota-mediated metabolic health. This study also 
provided insight into the detrimental effects of impaired CB2 signaling that should 
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DETAILED EXPERIMENTAL PROTOCOLS 
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PROTOCOL 1: IMMUNOHISTOCHEMISTRY: WHOLE-MOUNT ADIPOSE TISSUE 
Materials: 
4% (w/v) Paraformaldehyde in PBS 
1% Triton X-100 (Molecular Probes, ThermoFisher, HFH10) 
1% (w/v) BSA in PBS 
Antibodies 
BODIPY 558/568 C12 (Molecular Probes, ThermoFisher, D3835) 
Hoechst 33342 (Molecular Probes, ThermoFisher, H21492) 
Microscope slides  
Coverslips  
10 mL syringe  
16-gauge needle 
Fluoromount-G (eBioscience, 00-4958-02) 




Mouse FcR Blocker 
Alexa Fluor 488 anti-mouse F4/80 Antibody (Biolegend, 123120; BM-8) 
Alexa Fluor 633 Protein Labeling Kit (ThermoFisher, A20170) 
Purified anti-mouse Notch 1 Antibody (Biolegend, 130602; HMN1-12) 





1. Dissect epididymal fat pads from euthanized mice and mince into small 
pieces (~2-3 mm) using a scalpel. 
2. Wash tissue pieces in PBS. 
3. Fix in 4% paraformaldehyde for 3h at RT. 
4. Permeabilize with 1% Triton X-100 for 10m at RT. 
5. Block with 1% BSA + 1ug mouse FcR blocker for 40m at RT. 
6. Incubate in primary Ab overnight at 4°C (anti-F4/80, anti-NOTCH1, anti-
DLL4; [5ug/ml=1:100 dilution] in 1% BSA/PBS). 
7. Incubate in secondary Ab for 1h at RT (Rabbit anti-Hamster IgG—Alexa 
Fluor 633 [10ug/ml=1:100 dilution] in 1% BSA/PBS). 
8. Counterstain with BODIPY 558/568 [5uM] and Hoechst 33342 [40uM] for 
1hr at RT. 
9. Wash 3X with PBS and place on center of microscope slide. 
10. Make a boundary of Vaseline around the samples about 2mm high 
(matching tissue height) using a Vaseline-filled syringe.  
11. Fill inside of boundary with Fluoromount-G. 
12. Gently place coverslip onto the slide on top of the Vaseline boundary 
13. Lightly push down to meet the top of the sample. 
14. Seal edges with nail polish and let dry. 
15. Store 2-8°C in dark. 




PROTOCOL 2: BONE MARROW-DERIVED MACROPHAGE (BMDM) DIFFERENTIATION 
Materials: 
Sterile PBS 
Complete DMEM or DMEM/F12 (supplemented with 10% (v/v) heat-inactivated 
FBS, 1% (v/v) penicillin/streptomycin mixture, 2mM L-glutamine) 
Recombinant mouse M-CSF, carrier-free (BioLegend 576406) 
5-10mL syringe fitted with a 20-gauge needle 
Procedure: 
1. Dissect the tibias and femurs from euthanized 6-8-week-old naïve female 
C57BL6 mice. 
2. Flush the bones using an ice-cold PBS-filled syringe fitted with a 20-gauge 
needle. Use approximately 5-10 mL PBS per bone. 
3. Manually dissociate bone marrow by vortexing or passing through a 
syringe. 
4. Filter suspension through a sterile 70uM nylon mesh. 
5. Pellet cells (300xg, 7m, 4°C) and pour off supernatant.  
6. Resuspend cell pellet in 1mL RBC-lysis buffer and incubate 3-5m at RT. 
7. Add 10mL complete medium and pellet cells (300xg, 7m, 4°C). 
8. Resuspend in complete medium and count cells. 
9. Plate 2x106 cells in 10mL complete medium + 1U/mL M-CSF in a T-75 
flask or 100mm cell-culture dish. 
10. Incubate (37°C, 5% CO2, 95% humidity) for 7-10 days with the addition of 
5mL complete medium + 1U/mL M-CSF on Day 4. 
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PROTOCOL 3: MACROPHAGE: LYMPHOCYTE CO-CULTURE 
Materials: 
6- and 24-well tissue culture plates 
Complete RPMI 1640 medium (cRPMI) supplemented with 10% heat-inactivated 
FBS, 1% penicillin/streptomycin, 2mM L-glutamine, 10mM HEPES buffer, and 
0.0002% β-mercaptoethanol 
Sterile PBS 
DMSO and 100mM AM251 (Tocris 1117) 
Isotype control IgG and anti-DLL4 blocking mAb (BioLegend 130804) 
Lipopolysaccharide (LPS) (eBioscience 00-4976) 
Recombinant mouse cytokines, carrier-free (IFNγ: BioLegend 575302, IL-4: 
BioLegend 574302) 
ConcanavalinA (ConA) (Sigma C5275) 
Day 0: 
1. Plate 1.5x106 mature BMDM in 1.5mL cRPMI medium in 6-well plates. 
2. Add 0.5mL cRPMI containing DMSO (vehicle control), 10uM AM251, IgG 
(Isotype control) or 1ug/mL anti-DLL4 mAb. 
3. Incubate 1h (37°C, 5% CO2, 95% humidity). 
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4. Polarize BMDM by addition of 200uL cRPMI containing polarization 
factors (M1: 1ug/mL LPS + 500ng/mL IFNγ, M2: 10ng/mL IL-4). 
5. Culture for 24h (37°C, 5% CO2, 95% humidity). 
Day 1: 
1. Isolate cervical, axillary, popliteal, mesenteric, and inguinal lymph nodes 
from euthanized naïve 6-8-week-old female C57BL6 mice.  
2. Bring lymphocytes to single-cell suspension by filtering through a sterile 
70um nylon mesh and washing in cRPMI. Count cells. Keep on ice. 
3. Detach pre-treated and polarized BMDM from 6-well plates by gently 
scraping. Pellet BMDM by centrifugation (300xg, 7m, 4°C). Store 
supernatant at -20°C and wash BMDM 3X with PBS. 
4. Resuspend BMDM in cRPMI. Count. Adjust to 2x105 BMDM/mL.  
5. Plate 3x105 lymphocytes in 0.5mL cRPMI containing 2ug/mL ConA into a 
24-well plate in the wells that will contain a 1:1 co-culture ratio. Plate 1x105 
lymphocytes in 0.5mL cRPMI containing 2ug/mL ConA into the wells that 
will contain a 1:3 co-culture ratio. Plate 1 extra well for ConA stimulation 
control. Plate 1 well of lymphocytes in cRPMI without ConA as an 
unstimulated control. 
6. Add 500uL of each BMDM suspension to the appropriate lymphocyte 
wells. For the positive and negative ConA stimulation control wells add 
500uL cRPMI. The final ConA concentration is 1ug/mL for all wells. 
7. Culture for 48h (37°C, 5% CO2, 95% humidity). 
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